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ABSTRACT 
 
TITLE OF THE STUDY: 
“A study on the anaesthetic and analgesic effects of 
Intravenous Dexmedetomidine as premedication for Spinal anaesthesia’’. 
BACKGROUND AND OBJECTIVES:  
Spinal anaesthesia is a widely practiced anaesthetic technique for 
lower abdominal and lower limb surgeries. Dexmedetomidine is a highly 
selective α2 - adrenergic receptor agonist with a relatively high α2/α1 
activity. The present study evaluates the use of intravenous 
dexmedetomidine as premedication in bupivacaine induced spinal 
anaesthesia. 
METHODS: 
After approval of institutional ethical committee, a total of 60 
patients of ASA 1and 2 were enrolled in this study with written informed 
consent. Half the patients received i.v Dexmedetomidine 0.5μg/kg bolus 
over 10 minutes and the remaining half received same volume of normal 
saline similarly. Heart rate, systolic and diastolic blood pressures were 
recorded periodically; onset, level and duration of sensory and motor 
blockade assessed, and sedation score and time request for rescue analgesia 
were also noted. 
STATISTICAL ANALYSIS: 
 The data was analysed by SPSS 16.0 with independent t-test. 
RESULTS: 
In this quasi interventional study both the groups were comparable 
considering age, sex, height and weight. No significant biphasic change in 
heart rate, mean arterial pressure or cardiovascular variability was observed 
after administering Dexmedetomidine.  The requirement of Inj. Atropine 
and Ephedrine were comparable in both the groups. The time for two 
dermatome regression of sensory blockade, the duration of motor blockade 
and the time of request for post-operative analgesia were significantly 
prolonged in the study group. Furthermore, the sedation scores were 
relatively higher in the study group. 
IMPRESSION: 
This study proves that i.v Dexmedetomidine as premedication 
enhances the duration of sensory and motor blockade in Bupivacaine-spinal 
anaesthesia with stable hemodynamic parameters, improved analgesia and 
better sedation without ventilatory compromise. 
Key words: Dexmedetomidine, spinal anaesthesia, bupivacaine. 
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INTRODUCTION 
Spinal anaesthesia also called subarachnoid/intrathecal block is a 
popular technique carried out for a variety of infraumbilical operative 
procedures. The advantages are faster onset with effective sensory and 
motor blockade which has been well established and widely accepted. 
In this technique, to manipulate the spread of the local anaesthetic via 
the cerebrospinal fluid so as to provide an adequate block that ensures 
acceptable plane for the proposed procedure without needless extensive 
spread is a challenge to any anaesthesiologists1. 
Spread of the anaesthetic to higher levels may result in complications 
like paralysis of the intercostal muscles and the diaphragm causing 
respiratory crisis and may also affect the cardio-accelerator fibers which in 
turn affect the ability to control heart rate which can end up in cardio-
respiratory arrest and death in extreme cases if timely management is not 
provided. 
The surgical blood loss and other perioperative complications under 
spinal anaesthesia are less compared with general anaesthesia. The risks of 
general anaesthesia includes problems with airway management - difficult 
intubation in patients with anatomical abnormalities and possible need for 
postoperative ventilation for smokers or patients with irritable airway which 
can produce undesirable side effects in borderline hypertensives and 
geriatric patients. 
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Bupivacaine, an amide local anaesthetic, is the most commonly used 
drug for spinal anaesthesia. Over time different agents is being tried as 
adjuncts for delaying the span of spinal analgesia like epinephrine, 
phenylephrine, adenosine, magnesium sulphate, clonidine etc. the possible 
advantages of using these adjuncts include reduced local anaesthetic dose 
requirements which helps avoid the adverse effects of local anaesthetics, 
delayed onset of perioperative pain, reduced analgesic requirements, and 
better operating conditions for the surgeon. 
Dexmedetomidine is an eminent, potent α2-adrenoceptor agonist with 
1000:1 α2/α1selectivity and a half-life of 2-3hrs2. It decreases the local 
anaesthetic dose requirement, provides anxiolysis, sedation and 
sympatholytic activity, and improves perioperative hemodynamics by 
attenuating blood pressure and heart rate. The faster recovery of 
Dexmedetomidine has made its emergence as a sole agent for procedural 
sedation and for ICU sedation. The Federal Drug Administration (FDA) has 
approved the use of Dexmedetomidine as a sedative-analgesic in patients - 
adult and pediatric age group, undergoing minimal invasive procedures, 
with or without the need for tracheal intubation. The current clinical 
indications of Dexmedetomidine include: 
• sedation for mechanically ventilated patients in ICU (for up to 
24hrs as continuous infusion) 
• Procedural or perioperative sedation of non-intubated. 
Studies have shown a shorter onset of blockade and significantly 
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longer duration with intrathecal Dexmedetomidine as an adjunct with 
bupivacaine for regional anaesthesia with stable hemodynamic profile3. Only 
few studies have been conducted to study the effects of intravenous 
Dexmedetomidine during spinal anaesthesia. The present study assess the 
effects of intravenous Dexmedetomidine on patients posted for surgeries 
under spinal anaesthesia. 
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AIMS AND OBJECTIVES 
 
PRIMARY OBJECTIVE 
The objective of our present study is to evaluate the effects of 
intravenous Dexmedetomidine as premedication on the onset, level and 
duration of sensory and motor blockade, analgesia and sedation in patients 
posted for infraumbilical surgeries under Bupivacaine (hyperbaric, 0.5%, 
3mL) spinal anaesthesia. 
SECONDARY OBJECTIVES 
• The level of sedation achieved in comparison with control group. 
• To evaluate the post-operative analgesia requirements relative to 
control group. 
• To evaluate perioperative hemodynamic stability in the study group. 
• To assess possible complications. 
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HYPOTHESIS AND SCIENTIFIC JUSTIFICATION 
 
HYPOTHESIS:  
 Intravenous Dexmedetomidine as premedication for Bupivacaine 
spinal anaesthesia extended the span of sensory and motor blockade and the 
time of request for first rescue analgesia. It also provided arousable sedation 
without respiratory depression and maintained a stable hemodynamic profile 
throughout the perioperative period.  
 
SCIENTIFIC JUSTIFICATION OF THE STUDY: 
 Neuraxial block for lower abdominal surgeries are becoming widely 
popular owing to its many advantages over general anaesthesia.  Spinal 
anaesthesia consists of transient interruption of nerve transmission by 
injecting a local anaesthetic (Bupivacaine 15mg) solution in the 
subarachnoid space. The role of an anaesthesiologist is to render pain free 
surgical procedures. 
 Anxiety is the most prevalent presentation in patients in the 
perioperative period starting from few days prior to surgery and reaches its 
peak just before induction of anaesthesia. Anxiety is also an intraoperative 
problem in patients undergoing surgical procedures under regional 
anaesthesia which may be the reason for various manifestations like increase 
in oxygen consumption, respiratory rate and heart rate due to circulating 
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level of intrinsic catecholamines and their untoward effects. Control of 
anxiety and pain is a challenge to any anaesthesiologists in an attempt to 
control the metabolic derangements and for the safety and comfort of the 
patient. 
 Dexmedetomidine is an eminent, potent α2-adrenoceptor agonist that 
acts centrally. It has the ability to sedate, hypnotize and provide analgesia, 
thereby extending the duration of sensory and motor block acquired with 
intrathecal block while still preserving patient arousability and ventilatory 
function. It can be used as premedication, during induction of anaesthesia 
intravenously and as an adjuvant for intrathecal block with Bupivacaine. 
 This dissertation is a study on the effects of i.v Dexmedetomidine 
0.5mcg/kg as premedication for analgesia, sedation and prolongation of 
spinal anaesthesia in patients posted for surgeries under subarachnoid block 
with hyperbaric Bupivacaine 0.5% (3ml or 15mg).  
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REVIEW OF LITERATURE 
 
Studies have been carried out earlier to study the action of 
intravenous Dexmedetomidine on Bupivacaine spinal anaesthesia. Kaya FN 
et al4 conducted a double blind randomized placebo controlled trial study in 
2010, on the effects of intravenous Dexmedetomidine comparing it with 
intravenous midazolam on spinal anaesthesia, analgesia and sedation in 
patients posted for TURP on 75 patients belonging to American Society of 
Anaesthesiologists’ (ASA) 1 and 2 (n=25 in each group). Patients were 
given Dexmedetomidine 0.5 μg/kg, midazolam 0.05μg/kg or normal saline 
intravenously before intrathecal block with 15mg of 0.5% bupivacaine. 
Level of sensory block was relatively higher with Dexmedetomidine group 
(T4.6±0.6) than with midazolam group (T6.4±0.9; P<0.001) or saline group 
(T6.4±0.8; P<0.001). Time for sensory two dermatome regression was 145± 
26 min in the Dexmedetomidine group which lasted longer (p<0.001) than 
the midazolam group (106±39 min) or the saline group (97±27). Span of 
motor block was alike in all the three groups. Dexmedetomidine seemed to 
delay the first time request for rescue analgesia (p<0.01) compared to 
midazolam and saline group, and reduced the analgesic requirements 
(p<0.05). The Ramsay sedation score was higher in the Dexmedetomidine 
and midazolam group of patients than in the saline group (p<0.001). It was 
concluded that, intravenous Dexmedetomidine prolonged spinal bupivacaine 
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sensory blockade, but not midazolam, and it also provided arousable 
sedation and added analgesia. 
In the following sections basics of spinal anaesthesia, physiology and 
pharmacology of α2-adrenergic receptors and their agonists are briefed. 
 
SPINAL ANESTHESIA 
Also referred to as ‘subarachnoid block’ (SAB), or ‘intrathecal 
analgesia’. Spinal anaesthesia is produced when a local anaesthetic is 
injected into the subarachnoid space. 
History 
The first spinal analgesia was administered in 1885 by a neurologist 
James Leonard Corning when he accidentally pierced the dura mater while 
he was experimenting cocaine on the spinal nerves of a dog5,6. The first 
planned spinal anaesthesia was administered by August Karl G Bier on 16th 
August 1898 in Germany7 with the help of his assistant Hildebrandt, he 
administered 3ml of 0.5% (15mg) cocaine in a man. Bier and his assistant 
even tried spinal anaesthesia by injecting cocaine into each other’s theca8, 
and after a few further experimentation recommended it for surgeries of 
legs, but had to give it up due to cocaine toxicity. 
Anatomy 
Anatomy of vertebral column and of the lumbar vertebrae in 
particular is crucial for every anaesthesiologists. 
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Vertebral column:9 
The vertebral column is comprised of 33 vertebrae which protects the 
spinal cord. They include: 
• 7 Cervical.  
• 12 Thoracic.  
• 5 Lumbar.  
• 5 Sacrum (fused). 
• 4 Coccyx (fused).9 
 
Figure 1. Vertebral Column 
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In adults, vertebral column has four curves which have a significant 
effect on spread on the drugs administered intrathecally:9 
• Cervical and lumbar anterior Convexity curve 
• Thoracic and sacral anterior Concave curve9 
Vertebral ligaments9 
Vertebral column is bound together by ligaments (Fig 2.) for stability 
and elasticity.  
Supraspinous ligament, a strong fibrous cord connecting the apices of 
spinous processes and it continues as the ligamentum nuchae.  
Interspinous ligament: a thin membranous ligament, connects spinous 
processes, blend anteriorly with ligamentum flavum and posteriorly with 
supraspinous ligament.  
Ligamentum flavum: comprises of yellow elastic fibres, connects the 
adjacent lamina. The ligament begins at the root of articular processes 
laterally and extends posteriorly and medially to the point where the laminae 
join and form the spinous process. 
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Longitudinal ligaments: There are two longitudinal ligaments - 
anterior and posterior, bind the vertebral bodies together. 
 
 
 
 
Figure 2. Vertebral Ligaments 
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Lumbar vertebrae9 (Fig 3) 
A lumbar vertebra has: 
• A kidney shaped body. 
• Two pedicles directed backwards from the upper part of 
the body. 
• Two slender transverse processes. 
• Two laminae meeting posteriorly and enclosing the 
triangular vertebral foramen. 
• Thick, broad Spinous processes which are quadrilateral 
in shape. 
• Two upper and lower articular processes - prevents 
rotation but allow limited flexion and extension 
between the contiguous vertebrae. 
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Figure 3. Lumbar Vertebra 
 
Posteriorly vertebral canal is bounded by spinous processes and 
interspinous ligaments, by the pedicles laterally and by the laminae and 
ligamentum flavum posterolaterally. It extends superiorly from the foramina 
magnum and inferiorly ends in the sacral hiatus. It consists of the spinal 
cord, spinal membranes, adipose tissue, blood vessels, CSF and the roots of 
the spinal nerves. 
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SPINAL CORD11 
The brainstem continues as the spinal cord below the level of 
foramen magnum and terminates distally in the conical extremity known as 
conus medullaris as the delicate fibrous filament - the filum terminale, 
which descends to the back of first segment of coccyx from apex of conus 
medullaris, and cauda equina. In adult males the average length of the spinal 
cord is 45cms and in females 42cms, terminates at the level of L3 at birth 
and gradually rises with the progressing age to reach the lower border of L1 
in adults. 
 
Blood Supply of Spinal Cord11 (Fig. 4) 
A single anterior spinal artery (branch of vertebral artery) and two 
posterior spinal arteries (branch of inferior cerebellar artery) and the 
segmental spinal arteries (branch of intercostal and lumbar arteries) form the 
blood supply for the spinal cord. The major branch of spinal arteries, artery 
of Adamkiewicz supplies the lower thoracic and upper lumbar regions. 
Anterior spinal artery lies in the substance of pia mater over the anterior 
median fissure and supplies the lateral and anterior columns, which forms 
three quarters of substance of the cord. Thrombosis of this artery causes 
anterior spinal artery syndrome. The pairs of posterior spinal arteries supply 
posterior column of the cord. Venous drainage from the neck drains into the 
plexus of anterior and posterior veins, from the thorax into the azygos veins, 
Review of Literature  
 
15 | P a g e  
 
from the abdomen into the lumbar veins and from the pelvis into the lateral 
sacral veins. 
 
 
Figure 4. Blood Supply of Spinal Cord 
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Meninges12 
Three connective tissue coverings – the meninges, also protects the 
spinal cord along with the bony vertebral column. Duramater12, the tough 
outermost fibro elastic covering with an outer endosteal and an inner 
meningeal layer. Fibres of dura run longitudinally, so while inserting the 
spinal needle it is important to insert it in a way it only splits these fibres and 
not cut them so as to prevent unnecessary leak of CSF and to prevent post 
dural puncture headache therewith). Dural sac terminates at the lower border 
of S2, where it is pierced by filum terminale. Arachnoid Mater12 is a 
delicate, non vascular, middle covering closely attached to the dura, 
functions as a principal barrier to the drugs crossing in and out of the CSF.  
There is a subdural space, a capillary interval or a potential space between 
dura and arachnoid mater which contains serous fluid. Pia Mater12 is the 
innermost membrane, a vascular sheath which closely covers the brain and 
spinal cord. 
 
Subarachnoid Space or the Intrathecal space12 is the space between the 
arachnoid and pia mater, filled with cerebrospinal fluid and is composed of 
numerous arachnoid trabeculae, a delicate sponge like mass. 
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Cerebrospinal Fluid12 
It is a clear colourless fluid which resides in the space between the 
pia mater and the arachnoid mater, the cranial and spinal subarachnoid 
spaces and in the ventricles. Approximately 500ml of CSF is either secreted 
or formed by ultrafiltration from the choroidal plexus of the lateral 
ventricles per day, and is absorbed into the arachnoid granulations in the 
cerebral hemispheres.  
Properties: 
• Specific gravity: 1.003 to 1.009 at 370C. 
• Volume: 500ml is produced per day (30-80ml occupies the 
subarachnoid space from T1 to T12). 
• CSF pressure: 60 to 80 mmHg in lumbar space. 
• pH : 7.27 to 7.37 
• Composition: PCO2 : 48 mmHg, HCO3 : 23 mEq/L, Sodium : 135-
145 mEq/L, Calcium : 2-3 mEq/L, Phosphorous : 1.6 mg/dl, Magnesium : 2-
2.5 mEq/L, Chloride : 15- 20 mEq/L, Proteins : 23-38 mg/L 
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PHYSIOLOGY OF SUB ARACHNOID BLOCK 
In spinal anaesthesia, the local anaesthetic agent is deposited in the 
subarachnoid space, following which the there is a readily appreciable loss 
of sensation and muscle paralysis which reflects the direct blocking effect 
on transmission of the spinal nerve fibre impulses. In order of importance 
there are three sites of action of local anaesthetic agents instilled in the 
intrathecal space:  
• Primary - on the nerve roots of spinal cord.  
• Secondary - on the dorsal root ganglion and posterior-anterior 
horn synapses. 
• Limited and incomplete - on the spinal cord parenchyma in the 
ascending-descending tracts. 
Factors affecting spinal blockade include13 
• Type of drug. 
• Volume of solution. 
• Site of injection. 
• Rate of injection. 
• Specific gravity of solution - density and baricity. 
• Barbotage. 
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Factors affecting spread of blockade includes14 
1. Patient factors: 
• Age. 
• Height. 
• Position of the patient. 
• Spinal column configuration. 
• Cerebrospinal fluid volume. 
2. Technical factors: 
• Site of injection. 
• Direction of bevel of the needle. 
• Local anaesthetic dose. 
• Local anaesthetic baricity. 
• Local anaesthetic volume. 
The spinal nerve roots and the dorsal root ganglia are the principal 
sites of action. Nerves in the intrathecal space are highly accessible and 
easily anaesthetized, even with a small dose of local anaesthetic agent. The 
sensory and motor blockade reflects the direct effects of local anaesthetic on 
the spinal nerve roots. The smaller nerve fibers are affected first, and thick 
large motor fibers last. The sympathetic blockade is more diffuse and 
generally extends two to four segments above the level of motor blockade. 
The sympathetic blockade is first to occur and are last to recover and the 
motor nerve blockade is usually affected last and first to recover. 
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Sequence of spinal anaesthesia15 
• Vasomotor block: Dilatation of skin vessels and increase in the 
cutaneous blood flow. 
• Temperature fibers:  the unmyelinated C fibers - Cold first and 
warmth later. 
• Loss of temperature discrimination. 
• Pain - pin prick fibers – the myelinated A-delta fibers. 
• Loss of tactile sensation – the myelinated A-beta fibers. 
• Motor paralysis – the myelinated A-alpha fibers. 
• Pressure sensation. 
• Proprioception and vibratory sensation. 
Sympathetic blockade 
The level of sympathetic denervation determines the magnitude of 
cardiovascular responses to subarachnoid block, the higher the level of 
neural blockade the greater the change in the cardio-circulatory parameters. 
In partial sympathetic blockade, there is a reflex increase in sympathetic 
activity in the sympathetically intact areas which causes vasoconstriction 
that tends to compensate for the peripheral vasodilatation in the 
sympathetically denervated areas.  
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EFFECT OF SUBARACHNOID BLOCK ON DIFFERENT SYSTEMS 
Cardiovascular System40: 
The effects of autonomic denervation with higher levels of neural 
blockade, and added effects of vagal innervations together mediate the 
changes in cardiovascular system, which includes: 
• Fall in stroke volume 
• Venous and arterial vasodilatation thereby reducing the preload 
(venous return) and afterload (systemic vascular resistance) 
respectively. 
• Biphasic response in cardiac output – initial increase due to fall in 
systemic vascular resistance followed by eventual fall in cardiac 
output which reflects the block of cardiac efferent sympathetic 
fibres of T1-T4 causing loss of chronotropic and inotropic drive. 
• Bainbridge reflex or the blockade of cardioaccelatory fibers from 
T1-T4 results in bradycardia.  
• Systemic absorption of local anaesthetic causes depression of 
vascular smooth muscle and beta adrenergic blockade of 
myocardium resulting in fall in cardiac output. 
Block extending above the level of T4 is associated with extensive fall in 
BP.40 Bradycardia may also be due to lowering blood pressure in the right 
atrium owing to diminished venous return. 
Theories behind the reasons for fall in BP are:- 
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• Diminished cardiac output following reduced venous return 
• Dilatation of posterior arteries, capillaries and small venules. 
• Sympathetic blockade of the nerve supply to heart. 
• Sympathetic blockade of nerve supply to adrenal glands with 
consequent catecholamine depletion. 
• Ischemia and hypoxia of vital centres. 
• Compression of great vessels in abdomen by gravid uterus or intra 
abdominal tumors. 
During hypotension associated with spinal anaesthesia there is decrease 
in myocardial oxygen demands owing to decrease in preload, afterload, and 
heart rate. 
 
Cerebral Blood Flow 
Cerebral blood flow (CBF) in humans is maintained at constant levels 
by cerebrovascular autoregulatory mechanisms. The spinal anaesthesia 
induced fall in blood pressure can decrease regional cerebral blood flow in 
elderly and patients with pre-existing hypertension. 
 
Respiratory System 
Paralysis of the abdominal muscles is followed by decrease in vital 
capacity from a reduction in expiratory reserve volume. Blockade of 
intercostal and abdominal muscles is compensated by unaltered function of 
diaphragm and the accessory muscles of respiration. The respiratory arrest 
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associated with spinal anaesthesia is related to hypoperfusion of the 
respiratory centres in the brainstem and not due to Phrenic or inspiratory 
dysfunction. During spinal analgesia due to motor blockade and 
differentiation with reduction of sensory input to the respiratory centre, 
breathing becomes quiet and tranquil. Lowered arterial and venous tone 
lowers the work of the heart and thereby relieves any pre-existing 
pulmonary congestion. The pulmonary gas-exchange is preserved.  
 
Gastrointestinal System 
Neuraxial blockade of T6-T12 interferes with the splanchnic 
sympathetic innervations to the gastrointestinal tract leading to contracted 
gut and hyperperistalsis. Associated nausea and vomiting may be present 
owing to unopposed parasympathetic activity. Fall in hepatic blood flow 
parallels the fall in mean systemic arterial pressure which may affect the 
metabolism of amide anaesthetics. Subarachnoid block interrupt the 
hyperglycemic response to surgery and stress and hence is beneficial in 
diabetics, the response to insulin is enhanced and carries risk of 
hypoglycaemia35. 
 
Genitourinary System 
There is a predictable decrease in renal blood flow due to 
hypotension, but is of little physiologic significance until mean arterial 
blood pressure has fallen to about 50mmHg. There could be spinal 
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anaesthesia induced urine retention which may last longer as the paralysis of 
the small S2 to S3 autonomic fibers lasts longer than that of larger sensory 
and motor fibers. Uterine tone is preserved. Block of nerves from T11 and 
downwards helps in painless labour. Spinal anaesthesia reduces the 
threshold for shivering.  
 
ALPHA-2 ADRENOCEPTORS AND THEIR AGONISTS 
Distribution of α2-adrenoceptors 
Presynaptic α2-adrenoceptors (α2-AR) located in sympathetic nerve 
terminals and noradrenergic neurons in the CNS block the release of 
noradrenalin. Postsynaptic α2-AR are located in the peripheral nervous 
system, CNS, eye, liver, pancreas, kidney, platelets, and the adipose tissue.  
The medullary dorsal motor complex which has a high population of 
α2-AR, when activated they may probably be responsible for the blood 
pressure and heart rate effects of α2-AR agonists.17 Locus coeruleus is an 
important mediator of arousal and is the major site for the hypnotic action of 
α2-AR agonists. 18 
The locus coeruleus has numerous efferent connections. The 
subthalamic relay nucleus and the thalamus influence the cortical activity 
via noradrenergic fibres. The descending fibres in the dorsolateral funiculus 
tracts are responsible for the decrease in nociceptive communication at the 
spinal level. Furthermore, there are efferent fibres to the reticular formation 
with links to the vasomotor centres, and there are afferent connections from 
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the rostral ventrolateral medullary nuclei as well. High concentrations of α2-
AR have been found in the vagus nerve, intermediolateral cell column and 
in substantia gelatinosa. α2-A subtype adrenoceptors are found in the dorsal 
horn of the spinal cord whereas the primary sensory neurons contain both 
α2-A and α2-C adrenoceptors subtypes. 
 
Physiology of the α2-adrenoceptors 
These are primarily located on the presynaptic membrane; they 
modulate the release of norepinephrine (NE), while postsynaptic adrenergic 
receptors mediate smooth muscle vasoconstriction. Postsynaptic α2-AR is 
located in the peripheral nervous system, CNS, eye, liver, pancreas, kidney, 
platelets, and the adipose tissue. Quite recently, the predominant α2-AR was 
identified in human spinal cord and was named α2-AR subtype 3. 
 
Responses mediated by a2-adrenergic receptors 
Activation of the α2-adrenoceptors in the brain and spinal cord 
inhibits neuronal firing, responsible for hypotension, bradycardia, analgesia, 
and sedation. Other effects include decreased salivation, decreased 
secretions, reduced bowel motility; smooth muscle contraction; inhibition of 
renin release, increased GFR, and increased secretion of sodium and water; 
decrease in intraocular pressure; and reduced insulin release from the 
pancreas. 
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PHARMACOLOGY OF ALPHA-2 RECEPTOR AGONISTS 
Dexmedetomidine, a stereoisomer of medetomidine19, an imidazole 
derivative, is a very specific and short acting α-adrenoceptor agonist with 
1600 fold greater selectivity for α2 over α1 adrenoreceptors. The chemical 
name of Dexmedetomidine hydrochloride is (+)-4-(S)-[1-(2,3-
dimethylphenyl)ethyl]-1H-imidazole monohydrochloride; and the empirical 
formula is C13H16N2.HCL. (fig. 5). 
 
 
 
Figure 5. Structure of Dexmedetomidine 
 
The current clinical indications of Dexmedetomidine include  
• for ICU sedation in mechanically ventilated patients (for up to 24 hrs 
as continuous infusion)  
• Perioperative sedation or for sedation during minimal invasive 
procedures.  
The sedative dose is 1mcg/kg i.v bolus over 10 min followed by i.v infusion 
at the rate of 0.2 to 0.7 mcg/kg/hr. 
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Pharmacokinetics 
• Volume of distribution of around 200L.  
• Systemic clearance of 0.5 L/min after i.v infusion.  
• Exhibits a concentration-dependent nonlinear pharmacokinetic 
profile. At high concentrations of intravenous bolus, there is decrease 
in the initial volume of distribution and intercompartmental clearance 
owing to its peripheral vasoconstrictive action. 
• The drop in concentration of Dexmedetomidine results in 
vasodilatation due to its central effect (rapid administration of 
Dexmedetomidine can cause undesirable rise in blood pressure and 
altered pharmacokinetics).  
• The drop in the plasma concentration of Dexmedetomidine is 
predicted by its context-sensitive half-life (intramuscular route offers 
better predictability, and has relatively rapid onset of action, the peak 
plasma concentration occur within 15min20.  
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Mechanism of action (fig.6) 
Presynaptic α2-AR controls the release of norepinephrine and adenosine 
triphosphate (ATP) through a negative feedback mechanism. In short, 
presynaptic activation of the α2-AR inhibits the release of norepinephrine, 
terminating the dissemination of pain signals while postsynaptic activation 
of α2-AR inhibits sympathetic activity and thereby can decrease blood 
pressure and heart rate. These effects compiled provide analgesia, sedation, 
and anxiolysis thus avoiding the need for multiagent therapies22. 
 
 
Figure 6. Mechanism of action of Dexmedetomidine 
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PHARMACODYNAMICS 
 Dexmedetomidine is a complete α2-adrenoceptor whereas clonidine is 
a partial α2-adrenoceptor agonist. The selectivity of Dexmedetomidine over 
clonidine to α2-adrenoceptor is 1620:1 and 200:1 respectively. The 
selectivity is dose dependant, i.e., at low to medium or on slow infusion, 
high α2-selectivity is observed, whereas on high doses or rapid infusions of 
low doses were found to have both α1- and α2- activities.22 
 
Effects on CNS 
Dexmedetomidine provides dose dependant anxiolysis and sedation. 
Arousability is maintained even at deep levels of sedation with good 
association between the level of sedation and the bispectral EEG. 
Dexmedetomidine induces sleep by activating intrinsic non-rapid eye 
movement pathways. Activation of α2A-receptors in the locus coeruleus 
inhibits noradrenergic neurons.  
Ramsay et al24 evaluated Dexmedetomidine sedation of 401patients 
in the post operative period. Dexmedetomidine or saline was administered 
on arrival in the intensive care unit at 1.0 mcg/kg for 10 minutes, later 
titrated to 0.2 to 0.7 mcg/kg/hr to effect. Patients could be given propofol if 
necessary. Morphine was administered as analgesic – 60% of the patients 
who received Dexmedetomidine required no other sedative to maintain a 
Ramsay sedation score ≥ 3; 21% required < 50 mg of Inj. Propofol. In 
contrast, 76% of the patients in control group received propofol; of which 
59% required ≥ 50 mg of Propofol. Patients who received Dexmedetomidine 
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required significantly lower doses of morphine for pain relief (p<0.001). 
Continuously given throughout the ICU stay, Dexmedetomidine had no 
ventilatory depressive effects. Dexmedetomidine patients barely 
remembered pain or discomfort and majority of the patients maintained 
blood pressures within normal limits, without rebound 
hypertension.24Atelectasis, and rigors were observed to be more frequent in 
the control group. 
Dexmedetomidine was observed to decrease cerebral blood flow in 
dogs due to its interaction with halothane and isoflurane, with no sign of 
global ischaemia, it had only mild effect on ICP and has been shown as 
neuroprotective in animal models of brain ischemia.25 In animal models of 
incomplete cerebral ischemia and reperfusion Dexmedetomidine was found 
to minimize cerebral necrosis and improve neurologic outcome. It was 
shown that decrease in the intracerebral catecholamine outflow following 
injury resulted in less neural tissue damage with more desirable neurologic 
outcome. 
The hypnotic and supraspinal analgesic action of Dexmedetomidine 
are regulated by the hyperpolarisation of noradrenergic neurons, leading to 
stimulation of K+ channel, Ca2+ inhibition, inhibition of adenylcyclase which 
subdue neuronal firing in the locus coeruleus along with inhibition of 
norepinephrine release and its effect on the descending medullo-spinal 
noradrenergic pathway, secondary to activation of central α2-AR s. This in 
turn triggers neurotransmitters that reduce the histamine secretion providing 
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hypnosis similar to normal sleep, (with no ventilatory depression), making 
Dexmedetomidine a near ideal sedative agent. Subdued activity in the 
descending noradrenergic pathway, which mediates nociceptive 
neurotransmission, terminates the propagation of pain signals leading to 
analgesia.26 
 
Mechanism of analgesia 
α2-receptor agonists demonstrate analgesic effect when administered 
via the intrathecal or epidural route. The primary site of action is thought to 
be at the spinal cord. Narcotic sparing is observed with systemic use of 
Dexmedetomidine26. Dexmedetomidine restrain the release of substance P 
from the dorsal horn of the spinal cord, which is also responsible for primary 
analgesic effects.22 Dexmedetomidine has an inhibitory action on the locus 
coeruleus (A6 group) present at the brain stem. The prolongation of spinal 
anaesthesia is indicative of the supraspinal action of Dexmedetomidine 
when given intravenously. The noradrenergic innervation of the spinal cord 
emerges from the noradrenergic nuclei present in the brain stem which also 
includes the locus ceruleus, the A5, and the A7 noradrenergic nuclei. 
Neurons in the locus ceruleus are linked to the noradrenergic nuclei. The 
noradrenergic axon terminals reach lamina VII and VIII of the ventral horns 
of the spinal cord. The activity of the noradrenergic neurons is reduced by 
agonists acting at α2-AR on the locus ceruleus. Therefore, inhibition of the 
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locus ceruleus activates the noradrenergic nuclei and produce descending 
inhibitory effect on nociception.22 
27Al-Mustafa MM et al conducted a study on the effect of adding 
Dexmedetomidine to bupivacaine for neuraxial anaesthesia, 66 patients were 
randomly assigned into 3 groups, and each group received intrathecal 
bupivacaine 12.5mg, combined with normal saline for the patients allotted in 
group N, Dexmedetomidine 5 mcg in group D5, and Dexmedetomidine 10 
mcg in group D10. The mean time taken for the level of sensory block to 
reach T10 dermatome was 4.7 +/- 2.0 minutes in D10, 6.3 +/- 2.7minutes in 
D5 group, and 9.5 +/- 3.0 minutes in group N patients. The mean time to 
reach modified Bromage scale value 3 was found to be 10.4 +/- 3.4 minutes 
in D10 group of patients, 13.0+/- 3.4 minutes in D5 group, and 18.0 +/- 3.3 
minutes in group N patients. The regression time to reach S1 dermatome 
was 338.9 +/- 44.8 minutes in D10 group of patients, 277.1 +/- 23.2 minutes 
in D5 group, and 165.5 +/- 32.9 minutes in group N patients. The regression 
to Bromage 0 was observed to be 302.9 +/- 36.7 minutes in D10 group of 
patients, 246.4 +/-25.7 minutes in D5 group, and 140.1 +/- 32.3 minutes in 
group N patients. Onset and regression of sensory and motor block were 
significantly raised (N v/s D5, N v/s D10, and D5 v/s D10, p<0.001. It  was 
concluded that, Dexmedetomidine has effects on the onset and regression of 
sensory and motor block which is dose dependant when used as an adjuvant 
to bupivacaine in subarachnoid block. 
Review of Literature  
 
33 | P a g e  
 
Eid HEA et al conducted a study on 48 adult patients posted for 
anterior cruciate ligament reconstruction surgery; the patients were 
randomized into three groups. Each patient was given 3.5ml of 0.5% 
hyperbaric bupivacaine and 0.5ml containing either Dexmedetomidine 
10mcg (group D1), Dexmedetomidine 15mcg (group D2) or normal saline 
(group B). It was observed that intrathecal Dexmedetomidine in doses of 10 
mcg and 15 mcg significantly prolonged anaesthetic and analgesic effect of 
spinal hyperbaric bupivacaine in a dose dependent manner. 
A study24 was performed to assess the effects of intravenous 
Dexmedetomidine on low dose bupivacaine spinal anaesthesia in geriatric 
age group. Fifty one elderly patients undergoing TURP were randomized 
into two groups who received either 1.0mcg/kg Dexmedetomidine (group D, 
n=26) or normal saline (control group, n=25) i.v prior to spinal anaesthesia 
with 1.2 ml of 0.5% bupivacaine. The mean time for two segment regression 
(39 min v/s 78min for cold, 41min v/s 61 min for pinprick ) and that for 
motor regression (23 min Vs 46 min) were longer in patients belonging to 
group D than in the control group. The atropine - requiring bradycardia was 
observed more frequent in the D group (24.0% Vs 3.8%).The median 
sedation score ranged from 4 (2¬6) in the D group and 2 (1-3) in the control 
group (p,0.001) intraoperatively. Two patients in the group D showed 
peripheral oxygen desaturation of <90% intraoperatively. The duration of 
post-operative anaesthesia care unit stay was longer in the group D than in 
the control group (58 min Vs 96 min). Postoperative pain severity was lower 
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and the average time to first request for post operative analgesia was delayed 
in the group D compared to the control group (6.6 hr v/s 2.1 hr). It was 
concluded that iv Dexmedetomidine prolonged the time span of spinal 
anaesthesia and refined post-operative analgesia. However, more intense 
sedation with desaturation was observed with bradycardia occurring more 
frequently, and delayed recovery had to be anticipated in elderly patients. 
 
Effect on Sleep 
The α2-AR acts through the intrinsic sleep promoting pathways so as 
to produce their sedative effects. It provides a unique sedative quality 
described as “Clinically sedated yet arousable”. Despite sound levels of 
sedation with the administration of Dexmedetomidine there was no 
respiratory depression providing a wide safety margin.30 
 
Effects on CVS 
Both α1- and α2- post junctional receptors exist in arterial as well as 
venous vasculature where they both cause vasoconstriction. The α1- and α2- 
adrenoreceptors has diverse location, and utilisation of calcium. In the 
arterial vasculature, the α1-AR are junctional whereas the α2-AR are extra-
junctional, and vice versa in venous vasculature. α1-adrenoceptor activation 
produces vasoconstriction by using intracellular Ca2+  while the α2-AR 
controlled vasoconstriction utilizes extracellular Ca2+. This ensures that the 
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pressor response of α2-adrenoceptor agonists’ are more sensitive to calcium 
antagonists. 
Intravenous α2-adrenoceptor agonist administration causes decrease 
in heart rate as well as transient rise in arterial blood pressure and systemic 
vascular resistance, but results in a decreased cardiac output owing to the 
activation of postjunctional vascular α2-AR. This is followed by a longer 
lasting reduction in both heart rate and blood pressure due to a centrally 
mediated reduction in sympathetic tone and an increased vagal activity. 
Neither an exact location nor the exact receptors responsible for the central 
hypotensive action of α2-AR agonists have been discovered yet. Theories 
proposed that postsynaptic α2-AR and imidazoline receptors in the brainstem 
are involved.22 
The bradycardia commonly observed following administration of α2-
AR agonists may be a result of the central sympatholytic action of these 
drugs leaving an unopposed vagal tone. It can also be indicative of 
presynaptic-mediated reduction of norepinephrine release or a direct 
vagomimetic action.22 
Although bradycardia can be an issue with the administration of α2-
AR agonists, Dexmedetomidine has been shown to be protective against 
adrenaline-induced arrhythmias during halothane anaesthesia in dogs. This 
anti-arrhythmic action is supposedly due to activation of imidazoline 
receptors.30 α2-AR are not known to cause any direct effects on the 
myocardium. α2-AR mediated decrease in sympathetic tone and increase in 
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parasympathetic tone is responsible for reduced heart rate, systemic 
metabolism, myocardial contractility and systemic vascular resistance. In 
short, the myocardial oxygen requirements are reduced. 
Various studies reveal that the hypotension and bradycardia are 
produced when Dexmedetomidine is used as an adjuvant in spinal or general 
anaesthesia in normal doses, but is usually clinically insignificant. 
 
Effect on Respiratory System 
α2-AR seems to yield minimal effects on ventilation. Clonidine in 
doses up to 300 mcg seemed to lessen the resting minute ventilation and 
increase end tidal carbon dioxide. 31 
Dexmedetomidine has a biphasic effect on respiratory drive, low 
doses decrease and higher doses increase the resting minute ventilation. 
Dexmedetomidine in doses up to 2 mcg/kg produced mild ventilatory 
depression, but this was not significantly different from that observed with 
placebo.32 
The locus coeruleus is a key site for the action of α2-AR agonists. The 
locus coeruleus is involved in arousal response; therefore suppression of its 
activity by α2- AR agonists can cause a state similar to sleep with slight 
respiratory depression. α2-AR stimulation has no remarkable effect on 
hypoxic or hypercapnoeic ventilator drives. Similarly the combination of α2-
AR agonists with opioids does not cause further ventilatory depression. 
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Effects on Renal System 
Activation of α1-AR in the kidney causes redistribution of blood from 
the cortical to medullary areas owing to the increase in renal vascular 
resistance. Stimulation of α2-AR results in numerous effects that promote 
diuresis and natriuresis. They reduce the secretion of vasopressin and 
antagonises its activity on renal tubules. α2-AR are also believed to inhibit 
the release of renin and increase the release of atrial natriuretic factor.33 
 
Neuroendocrine System Effects 
The α2-AR agonists causes neuroendocrine responses mainly related 
to their inhibition of sympathetic outflow and therefore decreases the plasma 
levels of circulating catecholamines. Activation of α2-AR located on the beta 
cells of the islets of Langerhans causes short term direct inhibition of insulin 
release and clinical hyperglycaemia. α2-AR agonists also enhance the release 
of growth hormone and inhibit adipose tissue lipolysis.34 
 
Effects on GIT 
α2-AR control vagally mediated increases in gastric and intestinal 
motility and secretions. Stimulation of α2-AR inhibits water secretion as 
well as increases net absorption in the large bowel. For the same clonidine 
has been used to successfully treat diarrhoea. Stimulation of α2-AR reduces 
salivary secretions which can cause dry mouth and patient discomfort.35 
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Effects on Platelets 
Selective α2-AR agonists are known to cause platelet aggregation by 
stimulating α2-AR on platelets which requires high concentrations of α2-AR 
agonists, low concentrations decrease plasma adrenaline concentration. The 
net response may be a reduction in platelet aggregation. α2-receptor 
stimulation also causes release of nitric oxide, a potent inhibitor of platelet 
aggregation.36 
DRUG AND RECEPTOR INTERACTIONS 
α2-AR agonists and opioids are noted to share similar 
pharmacological effects, they have similar distribution in the brain and that 
they acts by the activation of the same transduction and effector mechanisms 
- G- proteins and potassium channel coupling. Hence, if α2-AR agonists and 
opioids are administered together they may display a synergistic action. It 
helps reduce the opioid dose requirement and decrease the respiratory and 
addictive side-effects therewith.37 
α2-AR agonists also share a synergistic action with benzodiazepines. 
Administration of verapamil, a calcium channel blocker prolong the duration 
of the hypnotic action of Dexmedetomidine, which reflects the reverse effect 
following the administration of a calcium antagonist. 
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BUPIVACAINE 
Pharmacology (53-56) 
Classification: aminoamide local anaesthetic 
Chemical name: 1-butyl 2-piperidyl formo - 2’6’- xylidine hydrochloride.  
It was first synthesized by a Swedish investigator Boaf Ekenstam. 
Structure-Activity Relationships 
Bupivacaine has an amide bond (-NHC-) between the hydrophilic 
hydrocarbon chain (which makes it water soluble) to the lipophilic aromatic 
ring (responsible for nerve penetration). Bupivacaine is available as racemic 
mixtures of S and R enantiomers and they totally differ in their 
pharmacologic profiles. (Ehlrich,1992). 
 
Mechanism of Action 
Mechanism of action of bupivacaine is similar to other local 
anaesthetics. The primary site of action is on the axon cell membrane on 
which it produces electrical stabilization and thereby prevents the large 
temporary increase in sodium ion permeability necessary for the propagation 
of the impulse, the resting membrane potential is preserved and inhibits 
depolarization in response to stimulation. There is an initial rise in the 
threshold for electrical excitation, the rate of rise of action potential is 
reduced and conduction slowed. In the due course propagation of the 
impulse fails. 
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The mechanism by which local anaesthetics block sodium 
conductance: 
• Local anaesthetics in their cationic form act on the receptors 
within the sodium channels in the cell membrane and block it. 
The local anaesthetic gain access to the sodium channel either via 
the lipophilic pathway directly across the lipid membrane, or via 
the axoplasmic opening. This mechanism is responsible for 90% 
of the nerve blocking effects of amide local anaesthetics. 
• The second mechanism of action is the membrane expansion 
which is a nonspecific action and is in contrast to the more 
specific drug - receptor interaction. 
DOSAGE 
As with all local anaesthetics the variation in the dosage of bupivacaine 
depends upon: 
• Area to be anaesthetized. 
• The vascularity of the tissue to be blocked. 
• The number of neuronal segments to be blocked. 
• Individual tolerance. 
• Technique manifested. 
Pharmacokinetics 
Bupivacaine is a weak base with a Pk of 8.1, but is commercially 
available as acidic solutions in order to make it more water-soluble. The 
clinically used intrathecal solution of 0.5% Bupivacaine also contains 8.25% 
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Dextrose which makes it a hyperbaric solution. The pH is around 5.5 and it 
has a specific gravity of 1.0227-1.0278. When the pH of the local 
anaesthetic solution is close to its Pk value, it makes the solution more 
unionized and lipid soluble which provides a faster onset of action. So, 
commercially available 0.5% hyperbaric Bupivacaine solution usually has a 
slow onset of action. Once vascular absorption occurs, it gets distributed in 
the vessel rich group of tissues initially, followed by distribution in the 
skeletal muscles and fat.  
• It is later Metabolized and eliminated by the liver. 
• Bupivacaine is 95% protein bound -mainly alpha-1 glycoprotein.  
• Volume of distribution is 73 L  
• Clearance 0.47 L/min 
• Elimination half time is 210 minutes (longer duration of action). 
Metabolism 
Possible pathways of metabolism include aromatic hydroxylation- 
dealkylation, amide hydrolysis and conjugation. (Pihlajamaki et al;1990). 
 
Side Effects 
• Allergic reactions 
• Systemic toxicity 
¾ CNS toxicity (>4mcg/ml) 
¾ CVS toxicity (>8mcg/ml) 
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• Others - transient radicular irritation, Cauda equine syndrome and 
anterior spinal artery syndrome. 
 
Uses of Bupivacaine: 
• Local infiltration at the site of wound. 
• Peripheral nerve blocks. 
• Epidural analgesia/anaesthesia. 
• Intrathecal anaesthesia. 
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MATERIALS AND METHODS 
STUDY DESIGN 
A quasi interventional study. 
STUDY PERIOD 
One year from September 2014 to September 2015 
STUDY POPULATION 
Patients posted for lower abdominal and lower limb surgeries. 
STUDY SETTING 
Department of Anaesthesia, Sree Mookambika Institute of Medical 
Sciences, Padanilam, Kulasekharam, Kanyakumari District. 
INCLUSION CRITERIA 
• Patients giving valid consent. 
• Patients belonging to American society of anaesthesiologist (ASA) 
grade 1 or 2. 
• Patients posted for elective lower abdominal or lower abdominal 
surgeries under Bupivacaine spinal anaesthesia. 
• Patients aged between 20-60 years of age. 
EXCLUSION CRITERIA 
• Patient refusal. 
• Patients with ASA grade 3 or more. 
• Patients posted for emergency surgeries and caesarean section. 
• Patients with history of alcohol/drug abuse. 
• Patients with known allergy to test drug. 
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• Patient with known contraindication to spinal anaesthesia 
(coagulopathy, infection at puncture site, pre-existing neurological 
deficits in lower extremities. 
SAMPLE SIZE 
Sample size was calculated using the formula 
(Zα+Z1-β)2 (σ12+σ22) ÷(μ1-μ2)2 
(Zα+Z1-β)2=7.9 
σ1
2 = standard deviation 1=31.51 
σ2
2 = standard deviation 2=34.8  
μ1= mean 1=190.1  
μ2=mean 2=165.2  
Calculated sample size=28  
Approximated sample size for the study=30 
 
STUDY METHOD 
After approval by the institutional ethical committee, ASA grade 1 
and 2 patients of either sex, aged between 20-60 years of age, weighing 50-
70kgs, posted for elective lower abdominal or lower limb surgeries, who 
met the inclusion criteria were enrolled for the study with written informed 
consent. 
Patients with history of alcohol or drug abuse, diabetes mellitus, 
cardiac issues, hypertension, COPD, psychological disorders, hepatic and/or 
renal disorders, spinal deformities or any contraindication to spinal 
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anaesthesia – patient refusal, coagulopathy, infection at the site of puncture, 
pre-existing neurological deficits, were excluded from the study. 
Patients were divided into two groups on an alternate basis – Group 
D – the study group and Group C – the control group. All the patients were 
visited on the previous day of the surgery and explained in detail about the 
anaesthetic procedure, reassured and written informed consent taken. The 
patients were kept nil per oral 6hrs prior to surgery. On arrival to the 
premedication room 18G venous cannula was secured and all the patients 
were prehydrated with 500ml of lactated Ringer’s solution. Theatre was set 
ready with the necessary drugs including the emergency drugs, airway 
devices, defibrillator and other equipments. Standard monitors – continuous 
ECG, non-invasive blood pressure and pulseoximeter (SPO2) and 
capnography were attached and baseline parameters recorded.  
Preparation of the study drug 
1ml of Dexmedetomidine (DEXTOMID * 1mL containing 100mcg 
of Dexmedetomidine) was diluted to make up a total of 10mL with sterile 
water making it 10mcg of Dexmedetomidine per cc, and required amount of 
the drug according to 0.5mcg/kg dose was loaded in a 20cc syringe and 
diluted again to make up a total of 10mL with sterile water for iv bolus 
infusion over 10 minutes. 
Premedication for patients in Group D, included Inj. Ranitidine 50mg 
iv, Inj. Metoclopramide 10mg iv and Inj. Dexmedetomidine, 0.5mcg/kg 
which was diluted to make up a total of 10ml with sterile water and infused 
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intravenously over 10mins with the aid of an infusion pump half an hour 
before surgery, whereas patients in Group C received 10ml of normal saline 
intravenously instead of Dexmedetomidine over 10mins. The patients were 
positioned lateral decubitus and dural puncture performed at L3-L4 
interspace through midline approach with 25 G Quincke needle, 15mg 
(3mL) of 0.5% Hyperbaric Bupivacaine was injected intrathecally and were 
immediately positioned supine for the surgery. All the patients received 
oxygen at a flow rate of 4L/min throughout the procedure. 
 
OUTCOME VARIABLES 
Sensory blockade 
Sensory blockade was assessed using cold iced tube in the 
midaxillary plane every 2 minutes up to 10 minutes and thereafter every 10 
minutes from the time of spinal block till 2 dermatome regression was 
achieved.  
Recovery time for sensory blockade was defined as two dermatome 
regression of anaesthesia from the maximal level of block. 
 
Motor blockade 
Motor blockade was assessed by Modified Bromage 
scale50immediately after sensory block assessment every 2 min for first 10 
minutes and every 10 minutes intra- and postoperatively. 
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• Modified Bromage scale 0 - no paralysis. 
• Modified Bromage scale 1- unable to raise extended leg. 
• Modified Bromage scale 2 - unable to flex knee. 
• Modified Bromage scale 3 - unable to flex ankle. 
Duration of motor block was considered as time for return to Modified 
Bromage scale 1.  
 
Sedation 
Sedation was assessed using Ramsay sedation score51at 10, 30, 50, 
70, 90, 110 and 120 minutes. 
• 1 - conscious or agitated. 
• 2 - cooperative or tranquilized. 
• 3 - drowsy but respond to command. 
• 4 - asleep but respond to glabellar tap. 
• 5 - asleep with sluggish response to tactile stimulus. 
• 6 - asleep and no response. 
Ramsay sedation score of 4 or more was considered excessive. 
 
Hemodynamic parameters 
The heart rate(HR),mean arterial blood pressure(MAP), peripheral 
oxygen saturation(SpO2),end tidal CO2 (ETCO2), respiratory rate(RR) were 
recorded before premedication, 2mins after premedication, before and after 
intrathecal block and every 5mins for 2hrs thereafter. 
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Fall in MAP below 20% of baseline or a systolic pressure less than 
90mmHg was considered as hypotension for the purpose of the study and 
was treated with incremental doses of Inj. Ephedrine and a bolus 
administration of 250ml RL over 10 minutes. 
Heart rate below 50bpm was considered bradycardia and was treated 
with 0.6mg Inj. Atropine iv. EtCO2 in excess of 50mmHg or respiratory rate 
below 12 breaths per minute was considered respiratory depression. 
 
Time to request for rescue analgesia 
Postoperative pain was measured using Visual Analog Scale(VAS). 
VAS of ‘zero’ to ‘ten’ where ‘zero’ indicated no pain and ‘ten’ indicated 
worst imaginable pain. Inj. Tramadol 50 mg iv was given for rescue 
analgesia if the VAS score was more than 3. 
 
DATA ANALYSIS 
Data obtained was coded and entered into Microsoft excel. The 
categorical data expressed in terms of rates, ratios and percentage and 
continuous data expressed as mean ± standard deviation (SD). Statistical 
Package for Social Sciences (SPSS 16.0) is used for the statistical analysis 
of the present study. Unpaired sample ‘t’ test is applied to find the statistical 
significant between the two groups. p value less than 0.05 (p<0.05) is 
considered statistically significant at 95% confidence interval. The datas are 
expressed in number, percentage, mean and standard deviation.  
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In the present study 33.3% in Group D were females and 66.7% 
males whereas in Group C 23.33% females and 76.76% were males. The 
demographic status is comparable in both the study groups. 
 
Table 2. Age Distribution 
Age 
Group D Group C Total 
 
N % N % N % 
 
<30 8 26.67 6 20.00 14 23.33 
 
31-40 6 20.00 12 40.00 18 30.00 
 
41-50 9 30.00 9 30.00 18 30.00 
 
51-60 7 23.33 3 10.00 10 16.67 
 
Total 
30 
100.0 
30 
100.0 60 100.0 
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Table-6: Hemodynamic parameters- Heart Rate  
HEART 
RATE 
GROUP D (N=30) GROUP C (N=30)
t p 
Mean sd Mean sd 
Base line 78.03 9.33 76.66 1.10 0.51 0.60 
5 minutes 76.06 8.83 75.73 1.13 0.12 0.89 
15 minutes 75.80 9.14 74.40 1.23 0.50 0.61 
30 minutes 74.70 1.01 75.33 1.18 -0.22 0.82 
45 minutes 74.20 1.13 74.93 1.11 -0.25 0.80 
60 minutes 73.40 1.14 75.06 1.13 -0.56 0.57 
75 minutes 73.93 11.42 74.60 12.23 -0.21 0.82 
90 minutes 74.60 1.02 74.33 1.16 0.09 0.92 
105 minutes 74.80 9.67 74.53 11.48 0.09 0.92 
120 minutes 74.80 9.20 74.86 11.54 -0.25 0.98 
135 minutes 74.93 9.71 74.80 11.15 0.04 0.96 
150 minutes 75.50 9.52 75.90 10.40 -0.54 0.58 
165 minutes 74.13 9.74 75.86 10.45 -0.58 0.50 
180 minutes 74.26 10.05 75.80 10.56 -0.52 0.55 
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Graph-5: Hemodynamic Parameters - Heart Rate 
 
 
The mean baseline heart rate was 78.03±9.33 in group D and 
76.66±1.10 in group C. In group D patients at 45, 60 and 75 minutes there 
was a gradual fall in heart rate but with no further significant biphasic 
changes throughout surgery when compared to group C . The mean HR 
from 105 to 180 minutes in group C is observed to have a steeper rise 
towards the latter half of surgery. 
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Table 7. Hemodynamic Parameters - Mean Arterial Pressure 
MAP 
GROUP D (N=30) GROUP C (N=30)
t p 
Mean sd Mean sd 
Base line 96.96 6.86 93.03 8.73 1.93 0.05 
5 minutes 91.73 9.42 80.93 1.31 3.65 0.001
15 minutes 89.03 7.58 79.96 1.07 3.76 0.001
30 minutes 86.86 8.04 80.06 1.11 2.71 0.009
45 minutes 84.73 8.87 78.40 8.83 2.77 0.008
60 minutes 83.90 8.23 77.40 7.26 3.24 0.002
75 minutes 82.93 7.87 78.66 9.02 1.95 0.05 
90 minutes 82.20 7.51 78.83 9.07 1.56 0.12 
105 minutes 81.43 7.31 82.46 11.26 -0.42 0.67 
120 minutes 80.53 7.13 86.50 11.71 -2.38 0.20 
135 minutes 80.96 6.48 89.36 11.02 -3.59 0.001
150 minutes 80.73 6.19 90.70 11.47 -4.18 0.001
165 minutes 80.83 6.76 91.96 10.96 -4.73 0.001
180 minutes 80.43 6.10 94.06 12.45 -5.38 0.001
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Graph-6: Hemodynamic Parameters - Mean Arterial Pressure 
 
 
 The baseline MAP was 96.96±6.86 in group D and 93.03±8.73 in 
group C, p value 0.05 suggesting that baseline MAP was comparable in both 
the study groups. A fall in MAP was observed with both groups following 
intrathecal block. The fall in MAP was steeper in group C up to 90 minutes 
following spinal anaesthesia, lowest reading was at 60 minutes - 77.40±7.26, 
and that in group D was 83.90±8.23, p=0.002 which makes the difference 
statistically significant. At 135 minutes the mean MAP of group D was 
80.96±6.48and that in group C was 89.36±11.02 which indicates a steep rise 
in MAP in group C, p=0.001. From the above observations it is to be 
assumed that rise and fall in MAP is significantly relatively steeper in group 
C when compared with group D. 
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 In group D 63.34% of patients had sensory block lasting for 121-180 
minutes, 33.33% had for 61-120 minutes, and for 3.33% the sensory block 
lasted for up to 180 minutes. Whereas in group C, all the patients had 
sensory block lasting for not more than 120 minutes before the initiation of 
dermatome level regression. From the observations of the mean values, 
sensory block duration was significantly higher in group D (138.33) than in 
group C (76), p=0.001. 
 
Table-13: Duration of Motor Block 
Duration of 
motor  block (in 
GROUP D GROUP C TOTAL 
N % N % N % 
61-120 0 0 11 36.67 11 18.33 
121-180 21 70.00 19 63.33 40 66.67 
181-240 9 30.00 0 0 9 15.00 
Total 30 100.0 30 100.0 60 100.0 
 
Graph-11: Duration of motor nerve block 
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Table-14: Time for return to Modified Bromage Scale to 0 
CATEGORY N Duration of motor 
block in minutes 
t p 
Mean sd 
Group D 30 179 1.08 9.23 0.001 
Group C 30 137.67 2.22 
 
 In group D 70% of the patients were noted to have a motor block 
duration of 121-180 minutes and in 30% it lasted for 181-240 minutes. In 
group C 63.33% of the patients had motor block lasting for 121-180 minutes 
and for 36.67 the block lasted not more than 180 minutes. From the 
observations of the mean values, motor block in group D (179) was 
significantly higher than that in group C (137.67), p= 0.001. 
 
Table-15: Time at request for first post operative analgesia 
Time 
(min) 
Group-D Group-C Total 
N % N % N % 
60-120 0 0 4 13.33 4 6.67 
121-180 1 3.33 21 70.00 22 36.67 
181-240 15 50.00 5 16.67 20 33.33 
241-300 12 40.00 0 0 12 20.00 
>301 2 6.67 0 0 2 3.33 
Total 30 100 30 100 60 100 
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Graph-12: Time at request for first post operative analgesia 
 
 
Table-16: Comparison of mean values of time to rescue analgesia 
CATEGORY N Time at request for 
first post-operative 
t p 
Mean sd 
Group D 30 241.67 3.47 10.94 0.001 
Group C 30 155.00 2.59 
 
 The time of request for first analgesia in the postoperative period in 
50% of the group D patients was between 181-240 minutes and for 40% 
between 241-300 minutes, whereas in group C 70% of the patient required 
rescue analgesia between 121-180 minutes and 16.67% between 181-240 
minutes. All the group C patients required rescue analgesia in less than 240 
minutes while 6.67% of the patients in group D requested for rescue 
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analgesia only after 300 minutes. The observations show that time of request 
for rescue analgesia in the postoperative period was significantly extended 
in group D (241.67±3.47) when compared to group C (155±2.59), p=0.001. 
 
Table-17: Ramsay Sedation Score 
Sedation 
score
Group D Group C Total 
N % N % N % 
2 4 13.33 30 100 34 56.67 
3 26 86.67 0 0 26 43.33 
4 0 0 0 0 0 0 
Total 30 100 30 100 60 100 
  
Table-18: Comparison of sedation scores 
Sedation Group D Group C Total 
score N % N % N % 
<4 30 100 30 100 60 100 
>4 0 0 0 0 0 0 
Total 30 100 30 100 60 100 
 
 86.67% of the patients in group D had a Ramsay sedation score of 3 
and 13.33% had a score of 2, whereas all the patients in group C had 
Ramsay sedation score of 2 only, this shows that sedation score of the 
patients in group D was significantly high. 
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DISCUSSION 
This is a quasi interventional trial completed in a period of one year 
in the Department of Anaesthesiology, Sree Mookambika Institute of 
Medical Sciences, Padanilam, Kulasekharam, Kanyakumari District. A total 
of 60 patients undergoing lower abdominal and lower limb surgeries under 
bupivacaine spinal anaesthesia were randomly divided into two groups on an 
alternate basis, Group D - the study group (n=30) and Group C – the control 
group (n=30). For patients in Group D Inj. Dexmedetomidine 0.5mcg/kg 
diluted in 10ml of sterile water was given as premedication intravenously 
over 10mins half an hour before surgery, whereas patients in Group C 
received 10ml of normal saline intravenously instead of Dexmedetomidine 
over 10mins.  
In this study male subjects formed the majority in both the groups, 
66.7% in Group D were males and 33.3% females whereas in Group C 
76.76% were males and 23.33% females. In both the groups majority of the 
patients belonged to age group between 31-50 years suggesting that both the 
study groups were comparable with regard to the demographic variables. 
The mean age was 39.93 in group D and 38.46 in group C. The mean height 
in group D was 159.60±5.39 and that in group C 162.60±6.68. The mean 
weight was 59.93±5.92 in group D and 67.23±4.05 in group C. In group D 
50% of the patients were ASA 1 and 50% ASA 2, whereas in group C 
46.67% were ASA 1 and 53.33 ASA 2. Thus both the groups were 
comparable with regard to height, weight and ASA grade. 
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Earlier studies38,39 have showed that bradycardia due to 
Dexmedetomidine as a premedication is long lasting. This reflects the 
decreased sympathetic outflow and circulating levels of catecholamines 
caused by administration of Dexmedetomidine. In this study, the mean 
baseline heart rate was 78.03±9.33 in group D and 76.66±1.10 in group C. 
In group D patients at 45, 60 and 75 minutes there was a gradual fall in heart 
rate but with no further significant biphasic changes throughout surgery 
when compared to group C. The mean HR from 105 to 180 minutes in group 
C is observed to have a steeper rise towards the latter half of surgery. 
Rapid infusion of lower concentration or bolus administration of 
larger concentration of Dexmedetomidine is known to produce rapid rise in 
blood pressure and fall in heart rate as long as the central sympatholytic 
effect remains, causing moderate decreases in both mean arterial pressure 
and heart rate from the baseline readings. But no biphasic change or 
significant cardiovascular variation was noted in the study probably 
reflecting the effect of sympathetic blockade associated with spinal 
anaesthesia, slow rate of administration, and adequate prehydration. 40 In a 
study 48 patients belonging to ASA I/II/III posted for TURP/TURT/TVT 
were randomly divided equally into two groups receiving isobaric 
bupivacaine (12.5 mg) spinal anaesthesia. Patients in group D were given a 
loading dose of 1mcg/kg Dexmedetomidine intravenously over 10 min and 
0.5mcg/kg/hr for maintenance of anaesthesia; patients in group C (the 
control group) received normal saline instead. It was concluded that iv 
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Dexmedetomidine prolonged the sensory and motor blocks of bupivacaine 
spinal analgesia with excellent sedation and hemodynamic stability. Adverse 
effects were eluded by slow infusion of Dexmedetomidine. All patients had 
arousable deep levels of sedation without ventilatory depression, enabling 
their cooperation and better operating conditions for the surgeons. Decrease 
in the heart rate was more profound but insignificant in patients who 
received intravenous Dexmedetomidine compared to those who received 
normal saline. 26In a near similar study the lowest heart rate noted was 
61.7±6.2 in Dexmedetomidine group and 63.1±7.1 in normal saline group, 
which was statistically comparable. The incidence of bradycardia requiring 
management with atropine was relatively higher in group D (23.3%) than in 
group P (20.0%); but this difference was statistically not significant 
(p=0.754). 
Similarly in a study done by Hall JE et al41 to assess the safety and 
efficacy of two small dose infusions of Dexmedetomidine by evaluating 
sedation, analgesia and cardio respiratory function in seven healthy young 
volunteers who participated on three different occasions with random 
allocation to drug or placebo. Baseline parameters were recorded, and 
psychometric tests were carried out which included visual analog scale 
[VAS] for sedation; observer’s assessment of alertness/sedation scale; digit 
symbol substitution test; and memory. After a 10 minute initial dose of 
normal saline or 6mcg/kg/hr Dexmedetomidine, volunteers received IV 
infusions of normal saline, or 0.2 or 0.6 mcg/kg/hr Dexmedetomidine over 
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50 minutes. The Dexmedetomidine infusions provided similar, significant 
sedation (30%-60%), memory impairment (approximately 50%), and 
impairment of psychomotor performance (28%- 41%). Hemodynamic 
status, peripheral oxygen saturation, ETCO2, and respiratory rate were well 
preserved throughout. Analgesic requirement was reduced following 
Dexmedetomidine infusion. Small dose of Dexmedetomidine produced 
sedation, analgesia, and memory and cognitive impairment; and infusions 
produced arousable sedation, mild analgesia, and memory impairment 
without cardio respiratory compromise. 
4Another study reported an incidence of only two patients requiring 
atropine for bradycardia in Dexmedetomidine group and one in saline group 
(n=25). 
In the present study the baseline MAP was 96.96±6.86 in group D 
and 93.03±8.73 in group C, p value 0.05 suggesting that baseline MAP was 
comparable in both the study groups. A fall in MAP was observed with both 
groups following intrathecal block. The fall in MAP was steeper in group C 
up to 90 minutes following spinal anaesthesia, lowest reading was at 60 
minutes - 77.40±7.26, and that in group D was 83.90±8.23, p=0.002 which 
makes the difference statistically significant. At 135 minutes the mean MAP 
of group D was 80.96±6.48and that in group C was 89.36±11.02 which 
indicates a steep rise in MAP in group C, p=0.001. From the above 
observations it is to be assumed that both rise and fall in MAP is 
significantly relatively steeper in group C when compared with group D. 
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42In another study previously done there was fall in mean arterial 
pressure in both groups but was not clinically significant. And yet another 
study4 noted the lowest MAP in Dexmedetomidine group as 79.9±6.8 and in 
Saline group 83.2±7.2, which was statistically comparable. These results 
reflect the findings in our present study. A biphasic cardiovascular response 
has been demonstrated following administration of Dexmedetomidine; there 
was a transient increase in MAP and a reflex decrease in HR, due to direct 
effects of α2B-adrenoceptor stimulation of vascular smooth muscle, 
especially in the young healthy patients. This response can be reduced by a 
slow infusion of the drug over 10 min; but transient enhancement of  mean 
arterial BP and the fall in HR over the first 10 min has been demonstrated 
even at slower infusion rates. The transient increase in BP lasts for 5 to 10 
min, followed by fall in BP of 10-20% below the baseline value and by 
stable HR below the baseline values. These effects are probably caused by 
an inhibition of central sympathetic outflow overriding the direct action of 
Dexmedetomidine on the vasculature Postsynaptic stimulation of central α2-
AR’s cause sympatholytic effect leading to hypotension and bradycardia, an 
effect judiciously produced to attenuate the stress response of the ongoing 
procedure 43,44. Dexmedetomidine induced hypotension and bradycardia are 
readily reversed by ephedrine and atropine respectively.42 
In our study the need for ephedrine following fall in blood pressure 
had comparable levels in both the groups. 26In a study 2 out of 25 patients in 
Dexmedetomidine group and 4 out of 25 patients in Normal Saline group 
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developed hypotension. Mahmoud et al, in their study observed the 
incidence of hypotension comparable in both groups. 
In our study, peripheral oxygen saturation was maintained stable in 
both the groups at all time intervals. In the study conducted by Kaya FN et 
al4 they observed no ventilatory depression in any of the patients and the 
respiratory parameters (rate, oxygen saturation, and EtCO2) remained stable 
and within normal limits at all stages throughout the procedure. Another 
study40 showed higher oxygen saturation (> 95%) in all patients in the two 
groups in the perioperative period. 
In our study 86.67% of the patients in group D had a Ramsay 
sedation score of 3 and 13.33% had a score of 2, whereas all the patients in 
group C had Ramsay sedation score of 2 only, this shows that sedation score 
of the patients in group D was significantly high. It is noteworthy that even 
with excessive sedation (score of 3), the oxygen saturation remained 
comparable to the control group which is suggestive of Dexmedetomidine 
producing sedation without ventilatory depression, making it a near ideal 
sedative agent, the difference from other sedative agents being arousable 
sedation with better patient cooperation. Kaya FN et al4 in their study 
demonstrated excessive sedation in 2 out of 25 patients belonging to 
Dexmedetomidine group and 5 out of 25 in midazolam group and no 
incidence in the saline group.  
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The hypnotic and supraspinal analgesic action of Dexmedetomidine 
are regulated by the hyperpolarisation of noradrenergic neurons, leading to 
stimulation of K+ channel, Ca2+ inhibition, inhibition of adenylcyclase which 
subdue neuronal firing in the locus ceruleus along with inhibition of 
norepinephrine release and its effect on the descending medullo-spinal 
noradrenergic pathway, secondary to activation of central α2-AR s. This in 
turn triggers neurotransmitters that reduce the histamine secretion providing 
hypnosis similar to normal sleep, (with no ventilatory depression), making 
Dexmedetomidine a near ideal sedative agent81. Subdued activity in the 
descending noradrenergic pathway, which mediates nociceptive 
neurotransmission, terminates the propagation of pain signals leading to 
analgesia.45 
In our study in both the groups the highest level of block was at the 
level of T5. In both the groups majority of the patients attained a highest 
level of block at T6. Kaya FN et al in their study4 recorded the highest level 
of sensory block significantly higher (p<0.001) in Dexmedetomidine group 
of patients (T4.6±0.6) than in saline group of patients (T6.4±0.8). 
In the present study in group D 63.34% of patients had sensory block 
lasting for 121-180 minutes, 33.33% had for 61-120 minutes, and for 3.33% 
the sensory block lasted for more than 180 minutes. Whereas in group C, all 
the patients had sensory block lasting for not more than 120 minutes before 
the initiation of dermatome level regression. From the observations of the 
mean values, sensory block duration was significantly higher in group D 
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(138.33) than in group C (76), p=0.001. These results are invariable with the 
results obtained in a study conducted by Kaya FN et al4, a double blinded 
randomized placebo controlled trial study in 2010, on the effects of 
intravenous Dexmedetomidine comparing it with intravenous midazolam on 
spinal anaesthesia, analgesia and sedation in patients posted for transurethral 
resection of the prostate (TURP) on 75 patients belonging to American 
Society of Anaesthesiologists’ (ASA) I and II - 25 patients in each group. 
Patients were given Dexmedetomidine 0.5 μg/kg, midazolam 0.05μg/kg or 
saline intravenously before intrathecal block with 15mg of 0.5% 
bupivacaine. Sensory block was higher with Dexmedetomidine group 
(T4.6±0.6) than with midazolam group (T6.4±0.9; P<0.001) or saline group 
(T6.4±0.8; P<0.001).Time for sensory two dermatomes regression was 145± 
26 min in the Dexmedetomidine group, and lasted longer (p<0.001) than 
that in the midazolam group (106±39 min) or the saline group (97±27). 
Duration of motor block was alike in all the three groups. Dexmedetomidine 
seemed to increase the first time request for postoperative analgesia 
(p<0.01) compared to midazolam and saline group, and decreased the 
analgesic requirements (p<0.05). The maximum Ramsay sedation score was 
higher in the Dexmedetomidine and midazolam groups than in the saline 
group (p<0.001). It was concluded that, intravenous Dexmedetomidine 
prolonged spinal bupivacaine sensory blockade, but not midazolam, and it 
also provided sedation and added analgesia. 
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In group D 70% of the patients were noted to have motor block 
duration of 121-180 minutes and in 30% it lasted for 181-240 minutes. In 
group C 63.33% of the patients had motor block lasting for 121-180 minutes 
and for 36.67 the block lasted not more than 180 minutes. From the 
observations of the mean values, motor block in group D (179) was 
significantly higher than that in group C (137.67), p= 0.001. These results 
are invariable with results obtained in a study57 conducted on 50 ASA I/II 
patients posted for infra umbilical surgeries. Patients were randomly divided 
equally into two groups receiving isobaric bupivacaine (12.5 mg) spinal 
anaesthesia. Patients in group D were given a loading dose of 0.5mcg/kg 
Dexmedetomidine intravenously over 10 min and patients in group C (the 
control group) received normal saline instead. The motor block duration was 
significantly prolonged in group D than in the control group concluding that 
iv Dexmedetomidine prolonged the sensory and motor blocks of 
bupivacaine spinal analgesia with excellent sedation and hemodynamic 
stability.  
Another study2 demonstrated that combination of 12 mg of 
bupivacaine with a low dose (3 mcg) of Dexmedetomidine or 30 mcg of 
clonidine administered intrathecal significantly reduced the onset of motor 
block and extended both motor and sensory block when compared with 
bupivacaine alone. In this prospective, double blind study, 60 patients 
posted for TURP or transurethral resection of bladder tumor under spinal 
anaesthesia were randomly divided in to three groups to compare the onset, 
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duration and level of sensory and motor block, the hemodynamic variation 
and level of sedation following intrathecal bupivacaine with either 
Dexmedetomidine or clonidine as adjuvants. Group B were given 12 mg of 
hyperbaric bupivacaine, group D 12 mg of bupivacaine with 3 mcg of 
Dexmedetomidine and group C 12 mg of bupivacaine with 30 mcg of 
clonidine as adjuvants. Patients in groups D and C the onset of motor block 
was significantly shorter and sensory and motor regression times 
significantly longer in group B. In group D the mean time of sensory 
regression to the S1 level was 303 +/- 75 min, 272 +/- 38 min in group C 
and 190 +/- 48 min in group B (p < 0.001). The motor block regression to 
Bromage 0 was 250 +/- 76 min in group D, 216 +/- 35 min in group C and 
163 +/- 47 min in group B (p < 0.001). The onset and regression times were 
not significantly different between groups D and C. The MAP, HR and 
sedation levels were similar in the all the three groups intra and 
postoperatively. It was concluded that 3 mcg Dexmedetomidine or 30 mcg 
clonidine as an adjuvant to intrathecal bupivacaine, produces a similar 
prolonged motor and sensory block duration preserved hemodynamic 
stability and lack of sedation. 
Considering the present as well as the earlier studies it can be 
concluded that the effect of Dexmedetomidine on duration of spinal and 
motor blockade is independent on route of administration of 
Dexmedetomidine. Nevertheless, an intravenous route ensures a safer 
effective adjunct to subarachnoid block. The drawbacks of 
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Dexmedetomidine as an adjuvant for intrathecal block may include 
enhanced duration of motor block not suitable for ambulatory procedures. 
In our study the time of request for first analgesia in the postoperative 
period in 50% of the group D patients was between 181-240 minutes and for 
40% between 241-300 minutes, whereas in group C 70% of the patient 
required rescue analgesia between 121-180 minutes and 16.67% between 
181-240 minutes. All the group C patients required rescue analgesia in less 
than 240 minutes while 6.67% of the patients in group D requested for 
rescue analgesia only after 300 minutes. The observations show that time of 
request for rescue analgesia in the postoperative period was significantly 
extended in group D (241.67±3.47) when compared to group C (155±2.59), 
p=0.001. These findings are invariable with the results of a similar study26 
carried out to establish that iv Dexmedetomidine and not midazolam 
prolongs bupivacaine spinal anesthesia. The researchers noted that time of 
first request for rescue analgesia was 216±43 minutes in Dexmedetomidine 
group of patients, and significantly sooner in the saline group 122±34 
minutes (p<0.001). 
α2-receptor agonists demonstrate analgesic effect when administered 
via the intrathecal or epidural route. The primary site of action is thought to 
be at the spinal cord. Narcotic sparing is observed with systemic use of 
Dexmedetomidine24. Dexmedetomidine restrain the release of substance P 
from the dorsal horn of the spinal cord, which is also responsible for primary 
analgesic effects.22  
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A study48 demonstrated that Dexmedetomidine has an inhibitory 
action on the locus ceruleus (A6 group) present at the brain stem. The 
prolongation of spinal anaesthesia is indicative of the supraspinal action of 
Dexmedetomidine when given intravenously. The noradrenergic innervation 
of the spinal cord emerges from the noradrenergic nuclei present in the brain 
stem which also includes the locus ceruleus, the A5, and the A7 
noradrenergic nuclei. Neurons in the locus ceruleus are linked to the 
noradrenergic nuclei. The noradrenergic axon terminals reach lamina VII 
and VIII of the ventral horns of the spinal cord. The activity of the 
noradrenergic neurons is reduced by agonists acting at α2-AR on the locus 
ceruleus. Therefore, inhibition of the locus ceruleus activates the 
noradrenergic nuclei and produce descending inhibitory effect on 
nociception.22 
The hypnotic and supraspinal analgesic action of Dexmedetomidine 
are regulated by the hyperpolarisation of noradrenergic neurons, leading to 
stimulation of K+ channel, Ca2+ inhibition, inhibition of adenylcyclase which 
subdue neuronal firing in the locus ceruleus along with inhibition of 
norepinephrine release and its effect on the descending medullo-spinal 
noradrenergic pathway, secondary to activation of central α2-AR s. This in 
turn triggers neurotransmitters that reduce the histamine secretion providing 
hypnosis similar to normal sleep, (with no ventilatory depression), making 
Dexmedetomidine a near ideal sedative agent. Subdued activity in the 
descending noradrenergic pathway, which mediates nociceptive 
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neurotransmission, terminates the propagation of pain signals leading to 
analgesia.26 
To summarize, in our study, the use of intravenous Dexmedetomidine 
as premedication prolonged the duration of sensory and motor block while 
maintaining a stable hemodynamic profile and providing adequate arousable 
sedation. For the same, intravenous Dexmedetomidine seem to offer a 
clinical advantage as an adjunct to bupivacaine spinal anaesthesia, where a 
longer duration of anaesthesia is called for without the use of higher dose of 
local anaesthetic and to reduce the analgesic requirement. 
Dexmedetomidine, owing to its physiochemical properties of 
hemodynamic stability, is safe to be used in patients with limited functional 
reserve, and thereby omits the requirement for excessive fluids. 
The α2-AR acts through the intrinsic sleep promoting pathways so as 
to produce their sedative effects. It provides a unique sedative quality 
described as “Clinically sedated yet arousable”. Despite sound levels of 
sedation with the administration of Dexmedetomidine there was no 
respiratory depression providing a wide safety margin.30 
A limitation of this study is that the time of first request for rescue 
analgesia was used as the primary index for post operative analgesia instead 
of the standard VAS scores. This study also shows the relative shortcomings 
of the use of Dexmedetomidine in view of motor blockade prolongation 
which is undesirable postoperatively resulting in patient anxiety which is of 
particular importance in daycare surgeries. 
Conclusion  
 
79 | P a g e  
 
CONCLUSION 
 
The present study showed that intravenous Dexmedetomidine as 
premedication for Bupivacaine spinal anaesthesia prolonged the duration of 
sensory and motor blockade and the time of request for rescue analgesia. It 
also provided arousable sedation without respiratory depression and 
maintained a stable hemodynamic profile throughout the perioperative 
period. 
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SUMMARY 
Spinal anaesthesia also called subarachnoid/intrathecal block is a 
popular technique carried out for a variety of surgical procedures involving 
the lower abdominal and lower limb surgeries. Dexmedetomidine is a highly 
potent novel α2-adrenoceptor agonist with a higher α2/α1selectivity of 
1000:1. The aim of the present study is to assess the effects of intravenous 
Dexmedetomidine as premedication on the onset, level and duration of 
sensory and motor blockade, analgesia and sedation in patients undergoing 
lower abdominal and lower limb surgeries under Bupivacaine (hyperbaric, 
0.5%, 3mL) spinal anaesthesia. 
This is a quasi interventional trial completed in a period of one year 
in the Department of Anaesthesiology, Sree Mookambika Institute of 
Medical Sciences, Padanilam, Kulasekharam, Kanyakumari District. A total 
of 60 patients undergoing lower abdominal and lower limb surgeries under 
bupivacaine spinal anaesthesia were randomly divided into two groups on an 
alternate basis, Group D - the study group (n=30) and Group C – the control 
group (n=30). In Group D Inj. Dexmedetomidine 0.5mcg/kg diluted in 10ml 
of sterile water was given as premedication intravenously over 10mins half 
an hour before surgery, whereas patients in Group C received 10ml of 
normal saline intravenously instead of Dexmedetomidine over 10mins.  
In the present study 33.3% in Group D were females and 66.7% 
Summary  
 
81 | P a g e  
 
males whereas in Group C 23.33% females and 76.76% were males. The 
mean age in group D was 39.93 and 38.46 in group C and the mean weight 
was 59.93±5.92 in group D and 67.23±4.05 in group C. Both the groups 
were comparable regarding sex, age, height and weight. The biphasic 
change in heart rate and mean arterial pressure were insignificant. Arterial 
oxygen saturation did not fall below 97% in both groups throughout the 
study. The need for injection Atropine and Ephedrine was comparable in 
both groups. The sensory block duration was significantly higher in group D 
(138.33) than in group C (76), p=0.001, and the motor block in group D 
(179) was significantly higher as well than that in group C (137.67), p= 
0.001. The time of request for rescue analgesia in the postoperative period 
was significantly extended in group D (241.67±3.47) when compared to 
group C (155±2.59), p=0.001. The Ramsay sedation score of the patients in 
group D was significantly high - 86.67% of the patients had a sedation score 
of 3 whereas all the patients in group C had Ramsay sedation score of 2 
only. 
In short, it may be concluded that intravenous Dexmedetomidine as 
premedication for Bupivacaine spinal anaesthesia prolonged the duration of 
sensory and motor blockade and the time of request for rescue analgesia. It 
also provided arousable sedation without respiratory depression and 
maintained a stable hemodynamic profile throughout the perioperative 
period. 
 
Bibliography  
 
Page | 82  
 
 
BIBLIOGRAPHY 
1. Ankorn C, Casey WF. Spinal Anaesthesia - a practical guide 2000 ;            
( 12):21-34. 
2. Kanazi GE, Aouad MT, Jabbour-Khoury SI, Al Jazzar MD, 
AlameddineMM, Al-Yaman R, et al. Effect of low-dose 
dexmedetomidine or clonidine on the characteristics of bupivacaine 
spinal block. Acta Anaesthesiol Scand. 2006; 50(2):222-7. 
3. Panzer O, Moitra V, Sladen RN. Pharmacology of Sedative-Analgesic 
Agents: Dexmedetomidine, Remifentanil,Ketamine, Volatile 
Anesthetics, and the Role of Peripheral μ Antagonists.Crit 
CareClin2009; 25(3):451-69, vii. 
4. Kaya FN, YavascaogluB,Turker G, Yildirim A, Gurbet A, Mogol EB, et 
al. Intravenous dexmedetomidine, but not midazolam, prolongs 
bupivacaine spinal anesthesia. Can J Anaesth2010; 57(1):39-45. 
5. Corning, JL (1885). "Spinal anaesthesia and local medication of the 
cord". New York Medical Journal 42: 483–5. 
6. Turnbull DK, Shepherd DB. Post dural puncture headache: 
Pathogenesis, prevention and treatment. Br J Anaesth 2003; 91(5):718-
29. 
7. Brown DL. Spinal block in Atlas of Regional Anesthesia. 2nd ed., 
Philadelphia: WB SaundersCompany;1999 
Bibliography  
 
Page | 83  
 
8. dos Reis A Jr. Eulogy to August Karl Gustav Bier on the 100th 
anniversary of intravenous regional block and the 110thanniversary of 
the spinal block. Rev Bras Anestesiol2008; 58(4):409-24. 
9. Atkinson RS, Rushman GB, Davies NJH. Spinal analgesia: Intradural 
and Extradural. In: Lee's Synopsis of Anesthesia,11th ed., UK: ELBS; 
1993.p.691-745. 
10. Fettes PDW, Jansson JR, Wildsmith JAW. Failed spinal anaesthesia: 
Mechanisms, management and prevention. Br J Anaesth 2009; 
102(6):739-48. 
11. Perlas A, Chan VW. Neuraxial anesthesia and multiple sclerosis. CanJ 
Anaesth 2005; 52(5):454-8. 
12. Williams PL, Warwick R, Dyson M, Bannister LH. Gray’s anatomy. 
37thEd.  NewYork: Chruchill Livingstone;1989 
13. Healy TEJ, Cohen PJ. Wylie and Churchill-Davidson's A Practice of 
Anaesthesia 6th ed., London: Hodder Arnol Publication; 1995. 
14. Pinnock C, Lin T, Smith T. Fundamentals of Anaesthesia. 2nded., 
London: Greenwich Medical Media Ltd.; 2003. 
15. Greene NM. Distribution of local anesthetic solution within the 
subarachnoid space. Anaesth Analg1985; 64:715-30. 
16. Raymond Fink BR. Mechanisms of differential axial blockade in 
epidural and subarachnoid anesthesia. Anaesthesiology 1989; 70:815-
58. 
 
Bibliography  
 
Page | 84  
 
17. Langer SZ. Presynaptic regulation of the release of catecholamines. 
Pharmacology Reviews 1980; 32:337-62. 
18. Scheinin M, Schwinn D. The locus coeruleus: site of hypnotic actions of 
α2-adrenoceptor agonists Anesthesiology1992; 76:873-5. 
19. De Noyer M, Laveleye F, Vauquelin G, Gobert J, Wulfert E, 
Mivazerol.A novel compound with high binding specificity for α2-
adrenergic receptors: binding studies on different human and rat 
membrane. NeurochemInt1994; 24(3):221-9. 
20. Dyck JB, Shafer SL. Dexmedetomidine pharmacokinetics and 
pharmacodynamics. Anaesthetic Pharmacology Review 1993; 1:238-45. 
21. Ralph Getler, Clieghton H Brown, Mitchel H, Silvius N. 
Dexmedetomidine: a novel sedative analgesic agent. Baylor University 
Medical Centre Proceedings. 2001;14(1). 
22. Gertler R, Cleighton Brown H, Mitchell DH, Silvius EN. 
Dexmedetomidine: a novel sedative-analgesic agent. Proc (BaylUniv 
Med Cent) 2001; 14(1):13-21. 
23. Hossman V, Maling TJB, Hamilton CA, Reid JL, Dollery CT. Sedative 
and cardiovascular effects of clonidine and nitrazepam. 
ClinPharmacolTher1980; 28:167-76. 
24. Martin E, Ramsay G, Mantz J, Sum-Ping ST. The role of the α2- 
adrenoceptor agonist dexmedetomidine in postsurgical sedation in the 
intensive care unit. J Intensive Care Med. 2003; 18(1):29-41. 
25. Drummond JC. Dexmedetomidine, a α2-adrenergic agonist decreases 
Bibliography  
 
Page | 85  
 
cerebral blood flow in the isoflurane anesthetized dog. 
AnesthAnalg1990; 70:624-30. 
26. Grewal A. Dexmedetomidine: New avenues. J Anaesthesiol 
ClinPharmacol2011; 27:297-302. 
27. Al-Mustafa MM, Abu-Halaweh SA, Aloweidi AS, Murshidi MM, 
Ammari BA,  AwwadZM, et al. Effect of dexmedetomidine added to 
spinal bupivacaine for urological procedures. Saudi Med J 2009; 
30(3):365-70. 
28. Eid HEA, Shafie MA, Youssef H. Dose-Related Prolongation of 
Hyperbaric Bupivacaine Spinal Anesthesia by Dexmedetomidine. Ain 
Shams Journal of Anesthesiology 2011; 4(2):83-95. 
29. Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN, Ozcan B. 
Intraoperativeinfusion of dexmedetomidinereducesperioperative 
analgesic requirements. CanJ Anaesth. 2006; 53(7):646-52. 
30. Hayashi Y, Sumikawa K, Maze M, Yamatodani A, Kamibayashi T, 
Kuro M, et al. Dexmedetomidine prevents epinephrine-induced 
arrhythmiasthrough stimulation of central α2-adrenoceptors in halothane 
anesthetized dogs. Anesthesiology 1991; 75:113-7. 
31. Ooi R, Pattison J, FeldmanSA.The effects ofintravenous Clonidine on 
ventilation.Anaesthesia 1991; 46:632-3. 
32. Belleville JP, Ward DS,Bloor BC, Maze 
M.EffectsofintravenousDexmedetomidinein humans. Anesthesiology 
1992; 77:1125-33. 
Bibliography  
 
Page | 86  
 
33. Smyth DD, Umemura S, Pettinger WA. α2-adrenoceptor antagonism of 
vasopressin-induced changes insodium excretion.Am JPhysiol 1985; 
248:F767-72. 
34. Masal A, Satta G, Alagna S, Anania V, FrassettoGA,Rovasio PP, et al. 
Effect of clonidine onstress-induced cortisolrelease during 
surgery.PharmacolRes Comm 1985; 17:293-8. 
35. Di Joseph JF, Taylor JA, Mir GN. α2-receptors in the gastrointestinal 
system: a new therapeutic approach. Life Sci 1984; 35:1031-42. 
36. Grant JA, Scrutton MC. Interaction ofselective α-
adrenoceptoragonistsandantagonists withhuman and 
rabbitbloodplatelets.Br J Pharmacol1980; 71:121-34. 
37. Salonen M, Reid K, Maze M. Synergistic interaction between α2-
adrenergic agonists and benzodiazepines in rats. Anesthesiology 1992; 
76:1004-11. 
38. Arain S R, Ebert TJ. The efficacy, side effects, and recovery 
characteristics of Dexmedetomidine versus propofolwhenused for 
intraoperativesedation. AnesthAnalg2002; 95:461-6. 
39. Aantaa R, Jaakola Ml, Kallio A, Kanto J, Scheinin M, Vuorinen J.A 
comparison of Dexmedetomidine, and α2-adrenoreceptor agonist, and 
midazolam as i.m premedication for minor gynaecological surgery. Br J 
Anaesth 1991; 67:402-9. 
40. Al-Mustafa MM, Badran IZ, Abu-Ali HM, Al-Barazangi BA, Massad 
IM, AlGhanem SM. Intravenous dexmedetomidine prolongs 
Bibliography  
 
Page | 87  
 
bupivacaine spinal analgesia. Middle East J Anesthesiol2009; 
20(2):225-31. 
41. Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, 
and analgesic properties of small-dose Dexmedetomidine infusions. 
AnesthAnalg2000; 90(3):699-705. 
42. Whizar-Lugo V, Gomez-Ramfrez I A, Cisneros-Corral R, Martfnez-
Gallegos N. Intravenous Dexmedetomidine v/s Intravenous Clonidine to 
prolong Bupivacaine Spinal Anesthesia. A Double Blind Study.2007; 
19(3):143-6. 
43. Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle 
W, Bekker AY. Monitored AnesthesiaCare with Dexmedetomidine: A 
Prospective, Randomized, Double-Blind, Multicenter Trial. 
AnesthAnalg.2010; 110:47-56. 
44. Ishii H, Kohno T, Yamakura T, Ikoma M, Baba H. Action of 
Dexmedetomidine on the substantia gelatinosa neurons of the rat spinal 
cord. Eur JNeurosci2008; 27:3182-90. 
45. Ustun Y, Gunduz M, Erdogan O, Benlidayi ME. Dexmedetomidine 
versus midazolam in out patient third molar surgery. J Oral Maxillofac 
Surg 2006; 64:1353-8. 
46. Nelson LE,You T,Maze M, FranksNP. Evidencethat themechanism of 
hypnoticactionindexmedetomidine andmuscimol-induced anesthesia 
converges onthe endogenous sleeppathway. Anesthesiology2001; 
95:A1368. 
Bibliography  
 
Page | 88  
 
47. Kanazi GE, AouadMT, Jabbour-Khoury SI,Al JazzarMD, 
AlameddineMM,Al-YamanR,et al.Effectoflow-dose dexmedetomidine 
or clonidine onthecharacteristics ofbupivacaine spinalblock. Acta 
AnaesthesiolScand2006; 50(2):222-7. 
48. Jorm CM,StamfordJA. Actions of thehypnotic anaesthetic, 
dexmedetomidine,onnoradrenaline release and cellfiring inrat locus 
coeruleus slices. Br J Anaesth1993; 71:447-9. 
49. RoudetC, MouchetP, Feuerstein C,Savasta M. Normal distribution of 
α2-adrenoceptors inthe ratspinalcordandits modification after 
noradrenergic denervation:A quantitativeautoradiographicstudy. 
JNeurosciRes 1994; 39:319-29. 
50. Stone LS,Broberger C, VulchanovaL, WilcoxGL, HokfeltT, Riedl 
MS,et al. Differentialdistribution of α2Aand α2C adrenergicreceptor 
immunoreactivityin the ratspinal cord.J Neurosci1998; 8:5928-37. 
51. BromagePR, Burfoot MF, Crowell DE,PettigrewRT. Quality of 
epiduralblockade.Influenceofphysicalfactors.BrJ Anaesth 1964; 36:342-
52. 
52. RamsayMA, Savege TM, Simpson BR,Goodwin R.Controlledsedation 
withalphaxalone-alphadolone. BrMedJ1974; 2(5920):656-9. 
53. .EjnarEriksson. Illustrated Handbook in localanesthesia.2nd Edition. 
Lloyd-luke(London UK):1979,13 
54. A.R Aitkenhead, G. Smith. Text book of Anesthesia. 3rd Edition. 
Churchill livingstone(United States of America):1996, 435-444.  
Bibliography  
 
Page | 89  
 
55. Goodman and Gilman. The pharmacological basis of therapeutics.11th 
Edition. McGraw Hill publishing division (United States of 
America):2006, 204-214. 
56. Robert K Stoelting. Pharmacology and physiology in anesthesia 
practice. 3rd Edition. Lippincott–Raven publishers (United States of 
America):1999, 77-112. 
57. SS Harsoor, D Devika Rani, Bhavana Yalamuru, K Sudheesh, S S 
Nethra. Effect of supplementation of flow dose intravenous 
dexmedetomidine on characteristics of spinal anaesthesia with 
hyperbaric bupivacaine. 77A2013.57 (3).265-269.  
58. Maze M, Tranquilli W: Alpha-2 adrenoreceptor agonists: 
Defining the role in clinical anaesthesia. Anesthesiology 
1991; 74:581-605.  
59. Gerlach AT, Dasta JF: Dexmedetomidine: An updated 
review. Ann Pharmacother 2007;41:245-252. 
60. Talke P, Richardson CA, Scheinin M, Fisher DM. 
Postoperative pharmacokinetics and sympatholytic effects of 
dexmedetomidine. Anaesthesia Analgesia 1997; 85:1136-42 
61. Paris A, Tonner PH. Dexmedetomidine in anaesthesia. Curr 
Opin Anaesthesiol 2005; 18: 412-8 
62. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The 
effects of increasing plasma concentrations of 
Bibliography  
 
Page | 90  
 
dexmedetomidine in humans. Anaesthesiology. 2000; 
93:382-94  
63. Talke P, Chen R, Thomas B, Aggarwall A, Gottlieb A, 
Thorborg P, Heard S, Cheung A, Son SL, Kallio A. The 
hemodynamic and adrenergic effects of perioperative 
dexmedetomidine infusion after vascular surgery. 
Anaesthesia Analgesia 2000; 90:834-9  
64. Gerlach AT, Dasta JF: Dexmedetomidine: An updated 
review. Ann Pharmacotherapy 2007; 41:245-252. 
65. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of IV 
Dexmedetomidine in Humans II. Haemodynamic changes. 
Anaesthesiology 1992; 77:1125-33. 
66. Villela NR, Nascimento junior P. Dexmedetomidine in 
Anaesthesiology. Rev Bras Anestesiol 2003 Feb; 53(1):97-l 
13. 
67. Kallio A, Scheinin M, Koulu M, Riitta Ponkilainen, Heikki 
Ruskoaho, Osmo Viinamaki, and Harry Scheinin. Effects of 
Dexmedetomidine, a selective α2 adrenergic agonist on 
haemodynamic control mechanism. Clinical pharmacology 
and therapeutics 1989; 46: 33-42. 
68. Duke P, Maze M, Morrison P. Dexmedetomidine: a general 
overview. International Congress and Symposium Series 
(221). 1998(theme issue): 13. 
Bibliography  
 
Page | 91  
 
69. De Wolf AM, Fragen RJ, Avram MJ, et al: The 
pharmacokinetics of dexmedetomidine in volunteers with 
severe renal impairment. Anesth Analg 2001; 93:1205-1209. 
70. Venn RM, Karol MD, Grounds RM: Pharmacokinetics of 
dexmedetomidine infusions for sedation of postoperative 
patients requiring intensive caret. Br JAnaesth 2002; 
88:669-675. 
71. Ramsay MA, Luterman DL: Dexmedetomidine as a total 
intravenous anaesthetic agent. Anesthesiology 2004; 
101:787-790. 
72. Guo TZ, Jiang JY, Buttermann AE, Maze M: 
Dexmedetomidine injection into the locus coeruleus 
produces antinociception. Anesthesiology 1996; 84:873-881.  
73. Venn RM, Bradshaw CJ, Spencer R, et al: Preliminary UK 
experience of dexmedetomidine, a novel agent for 
postoperative sedation in the intensive care unit. 
Anaesthesia 1999; 54:1136- 1142. 
74. Venn RM, Hell J, Grounds RM: Respiratory effects of 
dexmedetomidine in the surgical patient requiring intensive 
care. Crit Care 2000; 4:302-308. 
75. Nacif-Coelho C, Correa-Sales C, Chang LL, Maze M: 
Perturbation of ion channel conductance alters the hypnotic 
response to the alpha 2-adrenergic agonist dexmedetomidine 
Bibliography  
 
Page | 92  
 
in the locus coeruleus of the rat. Anesthesiology 1994; 
81:1527-1534. 
76. Talke P, Tong C, Lee HW, et al: Effect of dexmedetomidine 
on lumbar cerebrospinal fluid pressure in humans. Anesth 
Analg 1997;85:358-364. 
77. Ebert TJ, Hall JE, Barney JA, et al: The effects of increasing 
plasma concentrations of dexmedetomidine in humans. 
Anesthesiology 2000; 93:382-394. 
78. Hogue Jr CW, Talke P, Stein PK, et al: Autonomic nervous 
system responses during sedative infusions of 
dexmedetomidine. Anesthesiology 2002; 97:592-598. 
79. Riker RR, Fraser GL: Adverse events associated with 
sedatives, analgesics, and other drugs that provide patient 
comfort in the intensive care unit. Pharmacotherapy 2005; 
25:8S-18S. 
80. Aho M, Erkola O, Kallio A, et al: Dexmedetomidine 
infusion for maintenance of anaesthesia in patients 
undergoing abdominal hysterectomy. Anesth Analg 1992; 
75:940-946. 
81. Kanchan Gupta, Sunil Katyal, Sandeep Kaushal, Geeta 
Mittal, Randomised double-blind comparative study of 
dexmedetomidine and tramadol for post-spinal anaesthesia 
Bibliography  
 
Page | 93  
 
shivering. Indian Journal of Anaesthesia, 2014, 58 (3) : 257-
262. 
82. Annamalai A, Singh S, Singh A, Mahrous DE, Can 
Intravenous Dexmedetomidine Prolong Bupivacaine 
Intrathecal Spinal Anaesthesia? 2013;    J Anesth Clin Resm 
4:372. 
83. DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: A 
review of clinical applications. Curr Opin Anaesthesiol 
2008;21:457-61 
84. Yazbek-Karam VG, Aouad MA. Perioperative Uses of 
Dexmedetomidine. Middle East J Anesthesiol 2006;18:1043-
58 
85. Kim YS, Kim YI, Seo KH, Kang HR. Optimal dose of 
prophylactic dexmedetomidine for preventing postoperative 
shivering. Int J Med Sci. 2013;10:1327–1332. 
86. Usta B, Gozdemir M, Demircioglu RI, Muslu B, Sert H, 
Yaldiz A. Study to evaluate the effect of dexmedetomidine 
on shivering during spinal anaesthesia. Clinics (Sao Paulo). 
2011;66(7):1187-91. 
87. Andrew C. Kontak,  Ronald G. Victor,  Wanpen 
Vongpatanasin, Dexmedetomidine as a Novel 
Countermeasure for Cocaine-Induced Central 
Bibliography  
 
Page | 94  
 
Sympathoexcitation in Cocaine-Addicted Humans, 
Hypertension. 2013, 61: 388-394. 
88. Alka Shah, Ila Patel, Rachana Gandhi, Haemodynamic 
effects of intrathecal dexmedetomidine added to ropivacaine 
intraoperatively and for postoperative analgesia.Int J Basic 
Clin Pharmacol. 2013; 2(1): 26-29. 
89. Mahima Gupta, S. Shailaja, and K. Sudhir Hegde. 
Comparison of Intrathecal Dexmedetomidine with 
Buprenorphine as Adjuvant to Bupivacaine in Spinal 
Asnaesthesia. J Clin Diagn Res. 2014; 8(2): 114–117. 
90. MS Saravana Babu, Anil Kumar Verma, Apurva Agarwal, 
Chitra MS Tyagi, Manoj Upadhyay, Shivshenkar Tripathi. A 
comparative study in the post-operative spine surgeries: 
Epidural ropivacaine with dexmedetomidine and ropivacaine 
with clonidine for post-operative analgesia. Indian Journal 
of Anaesthesia. 2013, 57(4): 371-376. 
Appendix 
 
Page | I  
 
APPENDIX I 
INSTITUTIONAL HUMAN ETHICS COMMITTEE CLEARANCE 
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APPENDIX II 
CONSENT FORM 
PART 1OF 2 
INFORMATION FOR PARTICIPANTS OF THE STUDY 
 
Dear volunteers, 
 We welcome you and thank you for your keen interest in 
volunteering for this research project. Before you become a part of the 
study, it is important for you to understand why this research is being carried 
out. This form will provide you all the relevant details of this research. It 
will explain the nature, purpose, benefits, risks, discomforts, precautions and 
the information about how this project will be carried out. It is important 
that you read and understand the contents of this form carefully. This form 
may contain certain scientific terms and hence, if you have any doubts or if 
you want more information, you are to ask the study personnel or contact the 
person mentioned below before you give your consent and also at any time 
during the entire course of the project you are free to retreat from the study. 
 
Name of the Principal Investigator: Dr. Suzanne Prasad 
Postgraduate – M.D Anaesthesiology 
Sree Mookambika Institute of Medical 
Sciences, 
Kulasekharam 
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Name of the Guide :   Dr. V.G. Jayaprakash, MD 
Professor 
Department of Anaesthesiology 
Sree Mookambika Institute of Medical 
Sciences 
Kulasekharam, Kanyakumari District: 
Tamil Nadu 629161  
 
Name of the Co-Guide : Dr. Rommy Geever T, MD 
Assistant Professor 
Department of Anaesthesiology 
Sree Mookambika Institute of Medical 
Sciences 
Kulasekharam, Kanyakumari District: 
Tamil Nadu 629161 
 
Institution Details with Address: Sree Mookambika Institute of Medical 
Sciences, 
Kulasekharam 
Kanyakumari District – 629161 
Tamil Nadu 
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Title of the study:  
“A study on the anaesthetic and analgesic effects of intravenous 
dexmedetomidine as premedication for spinal anaesthesia.” 
 
Background information: 
Spinal anaesthesia is a widely practiced anaesthetic technique for lower 
abdominal and lower limb surgeries. Dexmedetomidine is a highly selective 
α2 - adrenergic receptor agonist with a relatively high α2/α1 activity. The 
present study evaluates the use of intravenous dexmedetomidine as 
premedication in bupivacaine induced spinal anaesthesia. 
 
Aims and Objectives: 
Primary objective 
The objective of our present study is to evaluate the effects of 
intravenous Dexmedetomidine as premedication on the onset, level and 
duration of sensory and motor blockade, analgesia and sedation in patients 
posted for infraumbilical surgeries under Bupivacaine (hyperbaric, 0.5%, 
3mL) spinal anaesthesia. 
Secondary objectives 
• The level of sedation achieved in comparison with control group. 
• To evaluate the post-operative analgesia requirements relative to 
control group. 
• To evaluate perioperative hemodynamic stability in the study group. 
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• To assess possible complications. 
Scientific justification of the study: 
Neuraxial block for lower abdominal surgeries are becoming widely 
popular owing to its many advantages over general anaesthesia.  Spinal 
anaesthesia consists of transient interruption of nerve transmission by 
injecting a local anaesthetic (Bupivacaine 15mg) solution in the 
subarachnoid space. The role of an anaesthesiologist is to render pain free 
surgical procedures. 
 Anxiety is the most prevalent presentation in patients in the 
perioperative period starting from few days prior to surgery and reaches its 
peak just before induction of anaesthesia. Anxiety is also an intraoperative 
problem in patients undergoing surgical procedures under regional 
anaesthesia which may be the reason for various manifestations like increase 
in oxygen consumption, respiratory rate and heart rate due to circulating 
level of intrinsic catecholamines and their untoward effects. Control of 
anxiety and pain is a challenge to any anaesthesiologists in an attempt to 
control the metabolic derangements and for the safety and comfort of the 
patient. 
 Dexmedetomidine is an eminent, potent α2-adrenoceptor agonist that 
acts centrally. It has the ability to sedate, hypnotize and provide analgesia, 
thereby extending the duration of sensory and motor block acquired with 
intrathecal block while still preserving patient arousability and ventilatory 
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function. It can be used as premedication, during induction of anaesthesia 
intravenously and as an adjuvant for intrathecal block with Bupivacaine. 
 This dissertation is a study on the effects of i.v Dexmedetomidine 
0.5mcg/kg as premedication for analgesia, sedation and prolongation of 
spinal anaesthesia in patients posted for surgeries under subarachnoid block 
with hyperbaric Bupivacaine 0.5% (3ml or 15mg).  
 
Procedure of the study: 
Spinal anaesthesia has different steps. Patient will first be preloaded 
with 500mL of RL through 18G cannula, premedication includes Inj. 
Ranitidine 50mg i.v, Inj. Metoclopramide 10mg slow i.v and Group I will 
be given Dexmedetomidine 0.5mcg/kg (over 10mins) and Group II – 10mL 
of normal saline, half an hour before the surgery. The Multiparameter 
monitors will be attached and the heart rate, blood pressure and oxygen 
saturation will be constantly recorded from the time of administration of 
premedication and continued postoperatively. 15mg of Hyperbaric, 0.5% 
heavy Bupivacaine will be administered intrathecally into L₃-L₄ after 
proper positioning of the patient and the sensory and motor block, sedation 
score and postoperative analgesia will be assessed throughout for the study 
purpose. 
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1. Expected risk of the participants: 
Tachy/bradycardia and/or hyper/hypotension 
2.  Expected benefits of the patients: 
There may not be any personal benefits, but this study will be 
beneficial for the betterment of the health science. 
3. Maintenance of Confidentiality: 
All data collected for the study will be kept confidentially and 
would reflect on general statistical evaluation only and would not 
reveal any personal details. 
4. Why have you been chosen to be in the study? 
You are undergoing spinal anaesthesia and fulfil the criteria of 
selection. 
5. How many people will be in the study? 60 
6. Agreement of compensation to the patient: No 
7. Anticipated prorated payment, if any, to the participant(s) of the 
study: Nil 
8.  Can I retreat from the study at any time during the study period? Yes 
9.  If there are any new findings / information, would I be informed?  : 
Yes 
10.  Expected duration of Participant’s participation in the study: 
Throughout the day of surgery 
11.  Any other pertinent information: No 
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12. Whom do I contact for further information? : Dr. Suzanne Prasad  
 
For any study related queries, you are free to contact 
Dr. Suzanne Prasad 
M.D Postgraduate student 
Department of Anaesthesiology 
Sree Mookambika Institute of Medical Sciences, 
Kulasekharam 
Mobile number: +918098890801 
e-Mail I.D: suzanne_szn07@yahoo.co.uk 
 
 
 
Place: 
Date:      
 
 
Signature of the Principal Investigator 
 
 
Signature of the Participant 
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CONSENT FORM 
PART 1 OF 2 
PARTICIPANTS’ CONSENT FORM 
 
 The principal investigator has explained to me the details of the 
research “a study on the anaesthetic and analgesic effects of intravenous 
dexmedetomidine as premedication for spinal anaesthesia” to be conducted 
in the Department of Anaesthesiology, Sree Mookambika Institute of 
Medical Sciences, Kulasekharam. She has explained to me that by being a 
part of this study no new medication will be tried on me. I am aware of my 
right to opt out of this study at any stage without any hindrance to my 
ongoing treatment. No additional financial burden will be placed on me by 
being part of this study. Data collected for the study will be kept under strict 
confidentiality and would not reveal any personal details. The principal 
investigator has also explained in detail the procedure of administering the 
drug before spinal anaesthesia and the possible adverse effects associated 
with its use. Keeping the above facts in mind I, whole heartedly, without any 
compulsion agree to participate in this study. 
 
Signature of the patient:   Signature of the investigator: 
Address of the patient:   Address of the investigator: 
Signature of the witness: 
Address of the witness: 
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APPENDIX III 
PROFORMA FOR ANAESTHESIA RECORD 
Pre-Anaesthetic Evaluation 
Date: 
Name of the patient:       Age/Sex: 
Address:        I.P No: 
 
History From: 
Surgical Diagnosis: 
Proposed Surgery: 
Previous Anaesthesia: 
Relevant Past History:  
 
Current Medications (if any): 
Known Allergies: 
General     Physical Examination: 
(Good/Fair/Sick/Conscious/Drowsy/Unconscious) 
Pulse rate:    Blood Pressure:  Temperature: 
Pallor:     Cyanosis:   Oedema: 
Height (cms):   Weight (kgs): 
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Airway Assessment:  M.P    T-M distance:       
M-O distance:   Neck Movements: full/limited/none 
Teeth: (poor/loose)  Micrognathia:  
Short muscular neck:  Morbid Obesity:  Others: 
 
Systemic Examination Findings: 
Pulmonary Examination:     (smoker/not) 
 
Cardiovascular Examination: 
 
Abdominal Examination:     (alcoholic/not) 
 
Neuro-muscular Examination: 
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INVESTIGATIONS AND LABORATORY REPORTS 
 
Haemoglobin:      LFT: 
TC:        Serum Bilirubin: 
DC:        Direct Bilirubin: 
ESR:        Indirect Bilirubin: 
Blood Sugar:    Fasting:          SGOT: 
     Post-prandial:         SGPT: 
     Random:          SAP: 
Blood Urea:      S. Protein: 
Serum Creatinine:     Total Protein: 
Blood Group and Rh factor:   Albumin Globulin ratio: 
Urine Routine:     BT: 
Serology:      CT: 
ECG:       Others: 
X-ray Chest: 
ECHO/TMT/Others:        
ASA Physical Status: 1 2 3 4 5 6 E 
Patient accepted for Anaesthesia:  Yes/No 
Plan of Anaesthesia: 
Pre-medications and Instructions: 
 
Name of the Anaesthesiologist:    Signature  
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APPENDIX IV 
Anaesthesia Record 
         Date: 
Name of the Patient:      
 Age/Sex: 
         I.P No: 
Anaesthesiologist:        
Surgeon: 
Procedure:        Position: 
Pre-procedure assessment: 
 Consent signed:    Chart Reviewed: 
 NPO since:    Full stomach:  
 Patient reassessed prior to anaesthesia:  
Pre-anaesthetic state:  
(Awake/calm/anxious/uncooperative/sedated/unconscious) 
Baseline vitals: Pulse rate:    Blood Pressure: 
   Respiratory rate:   Temperature: 
   SpO₂: 
Monitors and Equipment: 
Non-invasive B.P:   Continuous ECG:    Pulse 
Oximeter: 
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Anaesthetic Technique: 
Position of the patient:    Needle Type and size: 
Site: 
Drug:       Dose: 
IV Fluids: 
Intraoperative Medications: 
 
Urine output: 
 
Intraoperative Vitals monitoring: 
Time HR MAP SPO2 
5 mins    
15mins    
30 mins    
45 mins    
60 mins    
1h 15 mins    
1h 30 mins    
1h 45 mins    
2 h    
2 h 15 mins    
2 h 30 mins    
2 h 45 mins    
3 h    
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TIME SENSORY MOTOR 
0  
10  
20  
30  
40  
50  
60  
70  
80  
90  
100  
110  
120  
130  
140  
150  
160  
170  
180  
190  
200  
210  
220  
230  
240  
260  
280  
300  
320  
 
The highest sensory block level achieved: 
Recovery time for sensory blockade (two - dermatome regression):  
Recovery time for motor blockade to Bromage 2: 
Time to first request for analgesia: 
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The Ramsay sedation score at 
 
 
 
 
 
 
 
 
 
Postoperative status of the patient: 
B.P:    Pulse rate:   Temperature:  
SpO₂: 
Postoperative instructions: 
 
 
Signature of the Anaesthesiologist 
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1 32 M 160 69 2 68 130 96 107 99 66 128 86 100 100 67 126 72 90 99 68 120 72 88 99 66 118 68 85 98 65 116
2 34 F 154 67 1 76 124 84 97 98 77 98 66 77 99 78 104 58 73 98 75 94 60 71 99 74 110 62 78 98 73 88
3 22 M 159 65 2 58 92 64 73 98 56 96 50 65 99 45 100 56 71 99 54 104 56 72 99 55 102 54 70 99 58 106
4 38 F 161 68 2 72 120 74 89 99 70 94 60 71 98 71 98 64 64 98 73 92 60 71 100 74 98 68 78 98 77 100
5 42 F 157 71 1 87 130 90 103 98 85 91 61 71 99 83 100 65 77 97 85 100 60 73 99 86 100 59 73 99 85 104
6 46 F 162 70 2 77 110 66 81 97 78 94 56 69 98 75 94 56 69 99 76 90 52 65 98 75 92 50 64 98 78 94
7 26 M 167 68 1 84 130 90 103 100 86 120 76 91 99 85 120 74 89 100 83 110 70 83 98 83 98 76 83 99 83 96
8 48 M 153 62 1 65 124 74 91 100 68 120 62 81 99 67 110 56 74 100 64 100 50 67 99 65 98 58 71 99 62 100
9 52 M 158 66 1 58 130 80 97 97 52 96 60 72 98 48 90 52 65 97 51 98 56 70 100 55 100 62 75 100 54 100
10 46 M 164 60 2 67 110 68 82 98 65 106 58 74 98 64 104 54 71 98 66 102 52 69 98 63 98 50 66 100 62 102
11 52 F 148 72 1 73 124 78 93 98 75 91 61 71 97 73 100 65 77 98 73 100 60 73 99 75 100 59 73 99 73 104
12 34 M 159 68 2 89 130 86 88 97 88 114 68 83 98 85 110 60 77 99 84 96 62 73 99 86 104 64 77 98 85 90
13 38 M 164 66 2 54 124 82 96 97 53 90 70 77 99 57 96 80 85 100 54 100 70 80 100 56 98 72 81 97 54 100
14 40 M 169 62 1 85 130 94 106 99 87 120 74 89 98 86 120 80 93 99 88 120 80 93 99 85 110 70 83 98 83 110
15 42 F 172 63 2 79 110 76 87 99 77 90 56 67 99 74 96 60 72 99 78 100 72 81 98 73 100 60 73 99 72 110
16 38 M 168 69 2 84 120 80 93 99 83 110 70 83 98 82 90 46 61 97 83 96 46 63 98 84 96 56 69 98 85 96
17 36 F 156 66 1 68 120 80 93 98 68 110 68 82 97 56 110 60 77 98 59 110 60 77 99 58 90 52 65 99 64 100
18 40 M 154 68 2 87 124 84 97 100 85 92 52 65 98 86 124 82 96 98 86 124 66 85 99 85 130 74 93 100 87 120
19 26 M 162 70 1 92 124 62 83 99 93 96 60 71 99 92 94 62 73 99 94 92 58 69 100 92 98 54 69 97 93 94
20 28 M 158 72 2 84 120 76 91 98 86 130 78 95 100 84 120 76 91 97 86 134 88 103 100 85 120 80 93 100 83 104
21 24 M 166 67 2 78 110 70 83 99 76 102 72 82 100 76 104 72 83 99 71 120 80 93 99 72 110 76 87 99 71 110
22 38 F 163 69 1 75 140 90 107 97 74 140 90 107 100 73 120 70 87 100 76 120 70 87 99 75 110 70 83 98 77 96
23 48 F 155 61 1 62 124 88 100 98 61 90 60 70 100 62 100 64 76 100 63 100 60 73 98 61 98 59 72 97 63 100
24 56 M 174 59 1 85 120 72 88 99 82 96 62 73 98 83 88 46 60 99 84 96 60 72 98 83 96 56 69 98 85 98
25 44 M 175 68 2 96 130 90 103 100 91 134 88 103 99 92 120 73 89 98 92 130 76 94 98 93 110 63 79 99 95 96
26 54 M 166 63 2 75 110 70 83 97 76 110 70 83 98 78 120 76 91 97 77 110 70 83 98 75 120 80 93 100 76 120
27 28 M 167 74 2 68 120 80 93 98 65 120 80 93 98 65 120 80 93 98 64 124 84 97 97 67 110 80 90 99 65 110
28 32 M 170 76 2 76 124 82 96 99 77 90 50 63 97 74 120 80 93 99 76 110 70 100 97 77 110 70 83 98 73 110
29 34 M 169 70 1 92 130 90 103 98 90 140 100 113 99 90 120 80 93 99 89 120 70 87 99 84 110 80 90 97 86 120
30 36 M 168 68 1 86 110 72 85 98 82 112 74 87 97 81 116 76 89 98 88 114 78 90 98 86 116 72 87 99 85 118
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58 74 99 58 106 56 73 100 54 104 56 72 100 55 86 50 62 99 56 104 52 69 98 56 108 58 75 99 58 106
70 80 98 75 110 68 82 99 76 110 70 83 100 79 112 80 91 99 76 120 76 91 99 77 130 78 95 97 76 124
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54 70 98 63 94 52 66 98 62 98 54 69 98 63 102 58 73 97 64 108 58 75 98 62 106 52 70 98 66 104
60 75 98 75 99 63 75 99 75 97 61 73 99 73 104 69 81 99 75 120 80 93 99 74 120 80 93 99 75 120
58 69 100 81 110 76 87 99 82 110 72 85 99 84 124 76 92 98 86 110 70 83 98 82 120 80 93 100 83 120
70 80 97 52 92 68 76 98 51 100 70 80 98 53 100 68 79 100 52 100 66 77 98 55 110 70 83 100 58 110
60 77 97 88 112 60 77 97 84 100 60 73 98 85 120 80 93 99 88 120 80 93 97 86 130 86 101 99 89 130
70 83 100 74 110 68 82 99 79 110 70 83 99 78 104 64 77 98 76 136 96 109 99 77 140 92 108 98 75 130
52 67 98 83 106 64 78 97 85 110 70 83 99 83 110 70 83 98 83 120 70 87 100 86 120 80 93 98 84 120
60 73 99 51 100 60 73 98 52 100 60 73 99 54 100 70 80 97 55 110 70 83 100 56 120 80 93 99 58 120
72 88 100 88 114 62 79 100 85 120 70 87 100 86 128 78 95 100 85 120 80 93 99 84 120 80 93 100 86 134
56 69 98 91 94 58 70 100 92 92 56 68 99 92 98 52 67 98 93 94 56 69 98 92 104 58 73 99 91 106
64 77 99 85 100 60 73 98 82 98 60 73 98 81 104 70 81 99 82 110 70 83 97 83 120 80 93 98 82 124
70 83 100 69 110 68 82 97 70 110 70 83 97 72 104 64 77 98 70 136 96 109 98 68 140 92 108 97 74 130
72 80 99 74 92 68 76 97 73 96 74 81 100 74 110 70 83 99 77 120 74 89 99 74 110 70 83 99 75 120
60 73 99 64 98 58 71 98 63 96 60 72 99 66 100 70 80 98 64 110 68 82 100 63 124 76 92 97 62 124
60 73 98 84 94 52 66 99 82 90 48 62 98 81 92 48 63 97 85 90 46 61 98 86 94 48 63 98 84 96
60 72 98 94 98 58 71 99 92 100 60 73 98 93 100 60 73 100 92 110 76 87 98 94 120 88 99 99 91 124
80 93 99 75 110 70 83 99 76 130 90 103 97 77 130 90 103 100 74 130 80 97 100 77 120 80 93 99 76 120
70 83 97 66 110 70 83 99 68 110 60 77 98 64 120 80 93 99 66 120 80 93 97 62 130 80 97 98 65 130
70 83 97 78 134 74 94 98 79 110 70 83 99 75 120 74 89 97 74 120 80 93 99 77 114 78 90 98 79 130
80 93 99 90 130 100 110 98 84 130 80 97 100 85 140 90 107 98 82 140 90 107 98 80 120 80 99 100 82 120
74 89 98 83 116 76 89 99 84 118 72 87 100 82 110 74 86 99 87 114 76 89 100 84 118 72 87 99 88 112
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68 82 98 72 124 78 93 99 71 130 86 101 98 N N T8 70 120 130 2
54 71 99 60 108 54 72 97 61 106 54 71 98 Y N 76 70 110 120 2
70 88 98 75 130 80 97 97 77 130 80 97 99 N N T5 70 140 160 2
90 100 98 86 120 80 93 99 84 130 90 103 97 N N T6 80 130 150 2
54 67 98 74 94 56 69 98 75 96 56 69 100 N Y T8 80 150 190 2
80 93 99 87 130 86 101 99 85 134 86 102 98 N N T7 70 110 130 2
80 93 98 62 130 76 94 100 65 132 84 100 98 N N T5 70 130 160 2
82 96 98 64 130 90 103 100 56 134 92 106 99 Y N T6 80 110 120 2
56 72 99 63 106 54 71 99 62 108 56 73 98 N Y T5 70 120 150 2
90 100 100 76 120 80 93 99 78 130 90 103 97 N N T7 80 150 170 2
70 87 100 85 130 80 97 98 84 134 88 103 99 N N T8 80 120 120 2
78 89 99 56 110 80 90 98 61 120 90 100 97 Y N T6 70 160 180 2
90 103 98 87 130 90 103 97 90 130 90 103 98 N N T6 70 170 190 2
90 103 98 76 130 96 107 97 76 134 88 103 99 N N T7 80 140 160 2
80 93 99 84 130 80 97 99 86 120 80 93 98 N N T5 80 170 180 2
80 93 98 60 130 80 97 98 61 130 80 97 100 Y N T7 90 150 170 2
94 107 97 83 120 80 93 99 85 130 90 103 100 N N T7 70 130 150 2
60 75 98 94 108 62 77 98 92 102 54 70 99 N Y T8 70 150 170 2
84 97 99 83 120 80 93 98 84 130 88 103 98 N N T6 70 110 130 2
90 103 100 78 130 96 107 99 75 134 90 103 99 N N T8 70 120 140 2
80 93 98 76 130 90 103 100 79 130 90 103 98 N N T6 90 140 160 2
76 92 98 66 120 80 93 100 62 120 80 93 98 N N T5 90 180 190 2
48 64 98 85 98 50 66 100 81 96 52 67 97 N Y T5 70 120 130 2
86 99 99 92 110 88 95 100 93 124 90 101 98 N N T6 80 130 140 2
80 93 99 78 110 80 90 100 74 110 70 83 99 N N T7 80 170 190 2
90 103 99 63 132 82 99 100 62 120 80 93 100 N N T7 80 160 170 2
90 103 98 77 124 76 92 100 78 124 88 100 98 N N T5 70 180 210 2
80 93 98 86 134 84 101 99 82 140 90 107 99 N N T6 90 130 150 2
74 87 99 81 116 74 88 98 86 112 78 89 99 N N T6 70 120 130 2
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1 32 M 154 64 1 62 138 94 109 99 66 132 90 104 99 65 130 88 102 98 66 128 86 100 98 66 126 84 98 98 64 116 84 95 97 64 112 76 88 100 62
2 43 M 157 68 2 77 120 74 89 98 75 108 60 76 98 76 104 58 73 99 76 98 56 70 97 74 94 48 63 98 75 92 44 60 100 75 90 44 59 98 76
3 26 F 162 57 2 84 134 86 102 100 78 132 86 101 98 77 128 72 91 100 77 122 70 87 99 75 118 68 85 97 76 110 68 82 99 77 114 70 85 99 77
4 24 M 158 59 1 65 126 72 90 97 65 124 70 88 99 64 118 70 86 98 64 112 68 83 98 66 110 64 79 99 65 108 64 79 98 64 104 64 77 100 66
5 35 M 153 63 1 89 132 80 97 97 85 128 70 89 100 86 124 68 87 99 84 120 66 84 99 85 114 66 82 97 85 110 68 82 99 86 108 70 83 99 86
6 56 M 152 58 1 96 142 92 109 99 89 134 86 102 100 87 130 82 98 97 87 128 76 93 100 87 126 74 91 98 88 124 72 89 100 86 126 74 91 98 86
7 52 F 162 54 1 84 138 86 103 100 82 134 76 95 97 80 132 78 96 97 81 130 76 94 100 83 126 60 82 99 82 124 62 83 98 82 118 62 81 97 81
8 42 M 149 67 2 68 130 78 95 100 64 126 60 82 98 64 120 60 80 98 63 118 58 78 98 62 114 58 77 98 58 112 60 77 97 56 106 58 74 99 50
9 46 M 154 59 2 72 122 68 86 100 70 118 68 85 99 68 114 66 82 98 64 108 56 73 99 54 106 54 71 99 57 100 56 71 100 58 102 56 71 100 69
10 34 F 168 61 2 78 140 92 108 99 77 138 76 97 98 78 134 74 94 99 77 130 72 91 99 78 128 70 89 100 77 126 68 87 98 79 122 68 86 98 78
11 24 M 162 67 1 69 126 70 89 97 69 120 62 81 100 68 116 64 81 99 64 114 66 82 97 62 110 64 79 97 58 110 66 81 100 64 110 68 82 98 64
12 43 M 164 62 1 74 136 82 100 98 74 132 78 96 97 73 128 70 89 100 74 124 64 84 97 75 120 66 84 97 75 126 68 87 100 74 124 62 83 99 76
13 48 M 163 56 2 73 128 74 92 98 72 124 74 91 97 74 120 72 88 100 73 122 68 86 99 72 118 68 85 98 70 120 66 84 98 72 120 70 87 97 73
14 30 F 155 68 1 75 134 78 97 97 74 130 76 94 98 75 128 74 92 99 74 126 72 90 100 73 124 68 87 98 71 122 70 87 97 74 120 66 84 100 72
15 46 M 166 64 2 88 130 70 90 98 85 126 72 90 100 86 122 70 87 97 87 120 70 87 97 88 116 66 83 99 86 118 66 83 98 86 116 68 84 100 85
16 54 M 168 67 2 62 142 86 105 98 60 140 82 101 97 58 138 74 95 97 52 134 78 97 98 50 132 76 95 99 48 130 78 95 100 56 128 70 89 99 58
17 52 M 152 53 1 79 128 72 91 99 78 122 72 89 100 77 118 70 86 98 76 114 70 85 99 76 118 68 85 100 75 114 70 85 98 74 118 68 85 97 77
18 29 F 157 49 1 82 126 70 89 100 80 120 74 89 98 82 116 72 87 98 81 112 72 85 97 80 116 66 83 97 82 112 68 83 97 83 116 70 85 98 81
19 53 M 156 65 2 96 130 78 95 100 96 126 72 90 98 95 124 70 88 98 95 118 70 86 99 96 116 68 84 99 94 114 68 83 98 96 116 70 85 97 96
20 56 F 164 62 2 78 134 84 101 100 76 130 76 94 97 77 128 64 85 100 74 120 68 85 99 76 116 66 83 97 75 112 64 80 100 76 110 68 82 97 75
21 45 M 159 58 1 82 140 88 105 97 80 136 78 97 100 81 132 78 96 100 81 130 76 94 98 82 132 80 97 98 80 132 66 88 99 82 128 68 88 98 81
22 52 M 161 68 1 87 136 74 95 98 86 134 86 102 97 85 134 84 101 97 87 130 82 98 98 85 130 84 99 100 84 128 74 92 98 84 126 70 89 99 86
23 24 M 169 64 2 77 120 70 87 99 76 86 44 58 98 77 90 58 69 98 75 94 52 66 97 74 92 50 64 97 75 90 56 67 97 75 92 52 65 100 76
24 36 F 157 58 2 80 138 90 106 97 75 134 86 102 100 78 132 74 93 99 76 134 76 95 100 77 128 72 91 98 78 128 70 89 100 76 124 72 89 99 74
25 26 M 167 62 2 78 132 80 97 100 77 128 76 93 98 76 126 74 91 99 74 126 72 90 99 75 124 72 89 97 76 120 74 89 99 74 122 74 90 98 75
26 43 F 157 49 1 64 126 72 90 97 62 122 68 86 100 62 118 64 82 100 60 118 62 81 99 61 112 62 79 97 61 112 60 77 97 54 108 60 76 99 63
27 50 F 166 53 2 83 136 84 101 97 82 132 78 96 100 80 130 78 95 97 78 130 74 93 98 82 128 72 91 99 77 126 74 91 98 82 120 68 85 100 80
28 33 M 161 60 1 79 130 82 98 98 77 126 72 90 99 74 124 72 89 98 75 120 68 85 98 73 122 68 86 99 72 126 72 90 100 74 124 70 88 97 73
29 37 F 157 55 2 68 138 80 99 99 62 134 86 102 99 60 134 82 99 98 56 132 80 97 97 50 130 84 99 100 50 132 84 100 99 48 130 82 98 98 56
30 27 M 158 48 1 92 130 76 94 98 90 128 74 92 99 91 124 72 89 99 90 120 70 87 99 89 118 64 82 99 88 116 64 81 98 87 114 62 79 99 86
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Observation at regular intervals (Time in minutes) in GROUP D
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118 78 91 99 64 120 74 89 98 63 118 78 91 97 62 114 76 89 100 63 116 74 88 99 63 114 76 89 99 64 118 72 87 98 N N T7 110 180 220 3
92 48 63 97 75 90 46 61 97 75 90 48 62 98 76 94 50 65 99 74 96 52 67 99 75 94 56 69 99 75 92 58 69 99 N Y T5 160 180 240 3
110 68 82 98 75 112 68 83 99 76 112 64 80 99 77 110 64 79 98 77 110 62 78 98 75 112 68 83 98 76 112 70 84 98 N N T6 130 170 170 2
104 70 81 99 64 108 68 81 100 66 110 66 81 99 65 108 68 81 99 65 108 66 80 97 64 106 68 81 99 65 106 66 79 97 N N T8 160 180 300 3
106 68 81 99 85 108 70 83 99 84 106 70 82 98 88 110 68 82 100 85 108 68 81 97 86 110 66 81 100 87 108 64 79 100 N N T6 150 190 210 3
126 74 91 97 87 128 72 91 100 86 120 68 85 97 87 118 70 86 100 86 118 68 85 99 88 120 68 85 98 86 118 68 85 99 N N T7 120 170 220 2
120 68 85 97 80 118 56 77 98 81 116 56 76 99 82 114 60 78 99 83 114 62 79 98 82 116 64 81 97 83 114 64 81 98 N N T5 140 160 230 3
108 56 73 99 56 106 54 71 99 56 104 56 72 99 55 102 58 73 99 54 100 56 71 99 54 98 54 69 99 54 100 56 71 99 Y Y T7 160 180 310 3
98 52 67 100 68 94 52 66 99 68 102 54 70 100 66 102 54 70 98 66 100 56 71 97 66 98 56 70 100 69 100 54 69 98 Y Y T8 110 170 270 3
120 66 84 98 78 120 64 83 98 78 118 68 85 100 79 116 68 84 97 77 114 64 81 99 78 116 64 81 100 76 118 66 83 99 N N T6 150 160 250 3
106 66 79 99 63 108 68 81 100 65 108 58 75 100 66 112 66 81 97 63 118 64 82 99 64 120 68 85 99 68 122 70 87 98 Y N T8 160 180 230 3
126 66 86 98 76 118 68 85 100 74 116 62 80 100 74 116 66 83 99 74 116 64 81 98 75 118 68 85 98 74 114 66 82 99 N N T6 190 200 190 3
116 68 84 100 74 114 64 81 97 71 114 66 83 99 73 118 68 85 98 73 120 70 87 97 72 118 64 82 97 71 116 62 80 100 N N T7 150 190 200 3
124 68 87 97 73 124 68 87 98 72 126 70 89 99 74 126 68 87 100 75 120 64 83 100 70 118 66 83 100 70 118 68 85 99 N N T8 130 180 270 3
112 66 81 100 86 110 68 82 100 84 108 60 76 98 88 106 60 75 99 87 104 60 75 100 86 100 58 72 99 86 108 56 73 98 N N T6 120 180 260 3
126 68 87 100 58 122 70 87 98 58 124 68 87 99 57 122 64 83 100 57 118 68 85 99 57 122 70 87 98 55 118 70 86 99 Y N T5 170 200 210 3
114 68 83 100 76 112 68 83 99 76 110 68 82 98 74 110 68 82 98 77 108 68 81 98 75 106 68 81 98 76 110 68 82 100 N N T7 130 190 250 3
116 70 85 100 81 114 70 85 98 82 108 66 80 100 83 108 64 79 100 81 106 66 79 97 80 110 70 83 98 80 112 70 84 99 N N T6 160 190 270 3
118 70 86 98 95 120 72 88 100 94 116 68 84 99 96 118 72 87 97 94 120 72 91 97 95 116 66 83 99 96 118 68 85 98 N N T6 130 180 310 3
106 60 75 99 74 102 62 75 98 76 102 64 77 99 74 104 62 76 98 75 106 62 77 98 76 106 64 78 100 77 104 66 79 99 N N T7 120 170 260 2
126 70 89 97 80 128 68 88 97 82 126 72 90 98 81 128 70 89 98 78 124 68 87 99 78 122 64 83 97 79 122 68 86 97 N N T5 110 170 210 3
126 72 90 98 86 124 70 88 99 85 122 70 87 98 85 120 68 85 99 86 116 64 81 100 85 120 68 85 99 85 118 64 82 97 N N T6 110 160 280 3
90 54 66 99 74 92 56 68 98 75 94 52 66 98 73 90 56 67 99 74 92 54 67 99 75 90 48 62 98 73 92 52 65 99 N Y T5 150 190 270 3
122 70 87 98 76 120 68 85 99 77 118 68 85 98 78 118 68 85 98 78 120 72 88 100 76 118 64 82 100 76 118 70 86 98 N N T7 110 170 260 3
120 70 87 99 75 118 68 85 97 76 116 68 84 97 74 118 64 82 97 75 116 64 81 99 73 112 62 79 98 73 110 60 77 98 N N T6 120 190 210 2
106 62 77 100 62 108 64 79 100 61 104 58 73 99 63 102 62 75 98 61 104 62 76 99 60 102 64 77 99 61 100 60 73 100 Y N T7 140 180 220 3
116 64 81 99 81 114 62 79 99 80 118 70 86 99 76 120 72 88 100 75 120 70 87 98 80 118 68 85 97 78 114 68 83 99 N N T8 150 180 250 3
118 68 85 100 77 118 68 85 98 75 114 62 79 97 73 118 64 82 99 75 116 70 85 98 73 116 82 93 99 74 114 64 81 98 N N T6 150 190 210 3
128 78 95 99 58 126 74 91 99 62 126 74 91 99 64 124 76 92 99 63 120 74 89 99 61 122 76 91 98 60 124 72 89 98 Y N T5 120 170 240 3
110 62 78 99 87 108 60 76 99 86 110 62 78 99 85 110 64 79 98 84 112 62 79 100 82 112 64 80 97 81 114 64 81 99 N N T6 140 180 230 3
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